Exhibit
10.1


 


Matinas
biopharma holdings, Inc.


 


(a
Delaware corporation)


 


8,000
Shares of Series B Convertible Preferred Stock


 


PLACEMENT
AGENCY AGREEMENT


 


June
19, 2018


 


ThinkEquity


A
Division of Fordham Financial Management, Inc.


17
State Street, 22nd Floor


New
York, NY 10004


 


Ladies
and Gentlemen:


 


Matinas
BioPharma Holdings, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the
purchasers (each, a “Purchaser” and, collectively, the “Purchasers”), pursuant
to the terms and conditions of this Placement Agent Agreement (this “Agreement”) up to an aggregate
of 8,000 shares (the “Shares”) of Series B Convertible Preferred Stock, par value $0.0001 per share
(the “Series B Preferred Stock”). The offering and sale of the Shares of Series B Preferred Stock is
hereinafter referred to as the “Offering.” The Company hereby confirms its agreement with ThinkEquity,
a division of Fordham Financial Management, Inc. (the “Placement Agent”) to act as Placement Agent in
accordance with the terms and conditions hereof.


 


Each
Share of Series B Preferred Stock will have a stated capital of $1,000 per share and will initially be convertible into 2,000
shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”). Such Common
Stock of the Company into which the Shares are convertible are hereinafter referred to as the “Conversion Shares.”
In addition, dividends on the Series B Preferred Stock will be payable in shares of Common Stock pursuant to the Certificate of
Designation (as defined below). Such Common Stock of the Company which may be issued as dividends on the Shares are hereinafter
referred to as the “Dividend Shares.” The Shares and, where applicable, the Conversion Shares and the
Dividend Shares, are collectively referred to as the “Securities.”


 


The
terms of the Series B Preferred Stock will be set forth in the Certificate of Designation (the “Certificate of Designation”)
to be filed by the Company with the Secretary of State of the State of Delaware as an amendment to the Company’s Certificate
of Incorporation.


 




    	 	1	 



    	 



    

 


The
Company has filed with the Securities and Exchange Commission (the “Commission”) a shelf registration
statement on Form S-3 (No. 333-217106) covering the public offering and sale of certain
securities, including the Securities, under the Securities Act of 1933, as amended (the “1933 Act”)
and the rules and regulations promulgated thereunder (the “1933 Act Regulations”). As used herein “Registration
Statement,” means such registration statement as amended by any post-effective amendments thereto, including the
exhibits and any schedules thereto, the documents incorporated or deemed to be incorporated by reference therein pursuant to Item
12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof pursuant to Rule 430B under the 1933
Act Regulations (the “Rule 430B Information”). Each preliminary prospectus used in connection with the
offering of the Securities, including the documents incorporated or deemed to be incorporated by reference therein pursuant to
Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as a “preliminary prospectus.”
Promptly after execution and delivery of this Agreement, the Company will prepare and file a final prospectus relating to the
Securities in accordance with the provisions of Rule 424(b) (“Rule 424(b)”) of the 1933 Act Regulations.
Any registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations is herein called the “Rule 462(b)
Registration Statement” and, after such filing, the term “Registration Statement” shall
include the Rule 462(b) Registration Statement. The final prospectus, in the form first furnished or made available to the Placement
Agent for use in connection with the offering of the Securities, including the documents incorporated or deemed to be incorporated
by reference therein pursuant to Item 12 of Form S-3 under the 1933 Act, are collectively referred to herein as the “Prospectus.”
For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any
amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its
Electronic Data Gathering, Analysis and Retrieval system or any successor system (“EDGAR”).


 


SECTION
1. Agreement to Act as Placement Agent; Placement of Securities. On the basis of the representations and warranties herein
contained and subject to the terms and conditions herein set forth:


 


(a)
Appointment of Placement Agent. The Company hereby authorizes the Placement Agent to act as its exclusive agent to solicit
offers for the purchase of all or part of the Securities from the Company in connection with the proposed Offering. Until the
Closing Date (as defined in Section 1(e) below) or earlier upon termination of this Agreement pursuant to Section 9, the
Company shall not, without the prior written consent of the Placement Agent (which consent shall not be unreasonably withheld,
delayed or conditioned), solicit or accept offers to purchase the Securities otherwise than through the Placement Agent.


 


(b)
Reasonable Efforts. The Company hereby acknowledges that the Placement Agent has agreed, as agent of the Company, to use
its reasonable efforts to solicit offers to purchase the Securities from the Company on the terms and subject to the conditions
set forth in the Prospectus. The Placement Agent shall use reasonable efforts to assist the Company in obtaining performance by
each Purchaser whose offer to purchase Securities has been solicited by the Placement Agent and accepted by the Company, but the
Placement Agent shall not, except as otherwise provided in this Agreement, be obligated to disclose the identity of any potential
purchaser or have any liability to the Company in the event any such purchase is not consummated for any reason. Under no circumstances
will the Placement Agent be obligated to underwrite or purchase any Securities for its own account and, in soliciting purchases
of the Securities, the Placement Agent shall act solely as the Company’s agent and not as principal.


 




    	 	2	 



    	 



    

 


(c)
Solicitation of Offers. Subject to the provisions of this Section 1, offers for the purchase of the Securities may
be solicited by the Placement Agent as agent for the Company at such times and in such amounts as the Placement Agent deems reasonably
advisable. The Placement Agent shall communicate to the Company, orally or in writing, each reasonable offer to purchase Securities
received by it as agent of the Company. The Company shall have the sole right to accept offers to purchase Securities and may
reject any such offer, in whole or in part. The Company shall have the right, in its sole discretion, to reject any offer to purchase
Securities received by it, in whole or in part, and any such rejection shall not be deemed a breach of this Agreement.


 


(d)
Initial Public Offering Price. The Securities are being sold to the Purchasers at the following initial public offering
price: $1,000.00 per Share of Series B Preferred Stock.


 


(e)
Payment. Payment of the purchase price for, and delivery of, the Securities (the “Closing”) shall
be made at the offices of Meister Seelig & Fein LLP (“Placement Agent Counsel”), 125 Park Avenue,
7th Floor, New York, New York 10017, or at such other place as shall be agreed upon by the Placement Agent and the
Company, at 10:00 a.m. (New York City time) on June 21, 2018, or such other time not later than ten Business Days after such date
as shall be agreed upon by the Placement Agent and the Company (such time and date of payment and delivery being herein called
“Closing Date”). The term “Business Day” means any day other than a Saturday,
a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by law to close in New York, New
York.


 










At
the Closing, the Company shall deliver the Shares purchased on such Closing Date to the Placement Agent, which delivery may be
made through the facilities of the Depository Trust Company (“DTC”). Following the delivery of the Shares
by the Placement Agent to the Purchasers against payment therefor, the Placement Agent shall wire transfer, in immediately available
funds, the aggregate Purchase Price of the Shares purchased on such Closing Date, net of the Placement Fee (as defined Section
1(f) below) and the expenses set forth in Section 4 of this Agreement, to the Company. All actions taken at the Closing shall
be deemed to have occurred simultaneously on the Closing Date. Any Securities for which payment has not been received by the Company,
to the extent they have been delivered to the Placement Agent, shall be returned to the Company.




 


No
Shares which the Company has agreed to sell pursuant to this Agreement shall be deemed to have been purchased and paid for, or
issued and sold by the Company, until the appropriate corresponding number of Shares shall have been delivered to the Purchasers
or the Placement Agent via DTC against payment therefor. If the Company shall default in its obligations to deliver the Shares
to the Purchasers or the Placement Agent on behalf of the Purchasers as per such instructions, the Company shall indemnify and
hold the Placement Agent harmless against any loss, claim, damage or liability directly or indirectly arising from or as a result
of such default by the Company.


 


(f)
Placement Fee. As compensation for services rendered, on the Closing Date, the Placement Agent shall deduct a cash fee
(the “Cash Fee”) in an aggregate amount equal to seven percent (7%) of the gross proceeds received from the
sale of the Securities on the Closing Date. The Cash Fee is hereinafter referred to herein as the “Placement Fee”.
The Placement Agent may retain other brokers or dealers to act as sub-agents on its behalf in connection with the Offering, subject
to the Company’s prior consent, which consent shall not be unreasonably withheld, the fees of which shall be paid out of
the Placement Fee. Each broker or dealer retained by the Placement Agent to act as a sub-agent in the Offering shall be entitled
to rely on the representations, warranties and agreements of the Company contained in this Agreement as of such sub-agent was
a party hereto.


 




    	 	3	 



    	 



    

 


(g)
Purchase Warrants. The Company hereby agrees to issue and sell to the Placement Agent (and/or its designees) at the Closing
Date an option (“Placement Agent’s Warrant”) for the purchase of up to an aggregate of 240,000
shares of Common Stock, representing 1.5% of the Conversion Shares underlying the Shares sold in the Offering (assuming the sale
of 8,000 shares of Series B Preferred Stock in the Offering), for an aggregate purchase price of $100.00. The Placement Agent’s
Warrant agreement, in the form attached hereto as Exhibit A (the “Placement Agent’s Warrant Agreement”),
shall be exercisable, in whole or in part, commencing on a date which is one (1) year after the Closing Date and expiring on the
five-year anniversary of the Closing Date at an initial exercise price per share of Common Stock of $0.75, which is equal to 150%
of the initial conversion price of the Shares. The Placement Agent’s Warrant Agreement and the shares of Common Stock issuable
upon exercise thereof are hereinafter referred to together as the “Placement Agent’s Securities,”
and the shares of Common Stock included in the Placement Agent’s Securities are sometimes referred to as the “Warrant
Shares.” The Placement Agent understands and agrees that there are significant restrictions pursuant to FINRA Rule
5110 against transferring the Placement Agent’s Warrant Agreement and the Warrant Shares during the one (1) year period
following the Closing Date and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate
the Placement Agent’s Warrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative,
put or call transaction that would result in the effective economic disposition of such securities for a period of one (1) year
following the Closing Date to anyone other than (i) an selling agent or a selected dealer in connection with the Offering, or
(ii) a bona fide officer or partner of the Placement Agent or of any such selling agent or selected dealer; and only if any such
transferee agrees to the foregoing lock-up restrictions.


 


SECTION
2. Representations and Warranties.


 


(a)
Representations and Warranties by the Company. The Company meets the requirements for use of Form S-3 under the 1933 Act,
including General Instruction I.B.1 of such Form S-3. The Company represents and warrants to the Placement Agent and the Purchasers
as of the date hereof, the Applicable Time (as defined in Section 2(a)(iii)) and the Closing Date, and agrees with the Placement
Agent and the Purchasers, as follows:


 


(i)
Registration Statement and Prospectuses. The Registration Statement has been declared effective under the 1933 Act. No
stop order suspending the effectiveness of the Registration Statement has been issued under the 1933 Act, no order preventing
or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes
have been instituted or are pending or, to the Company’s knowledge, contemplated. The Company has complied with each request
(if any) from the Commission for additional information.


 


The
Registration Statement, at the time it became effective, complied in all material respects with the requirements of the 1933 Act
and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto, at the time
each was filed with the Commission, complied in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations.
Each preliminary prospectus delivered by the Company to the Placement Agent for use in connection with the Offering and the Prospectus
was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except
to the extent permitted by Regulation S-T.


 




    	 	4	 



    	 



    

 


The
documents incorporated or deemed to be incorporated by reference in the Registration Statement, any preliminary prospectus and
the Prospectus, when they became effective or at the time they were or hereafter are filed with the Commission, complied and will
comply in all material respects with the requirements of the Securities Exchange Act of 1934, as amended (the “1934
Act”) and the rules and regulations of the Commission under the 1934 Act (the “1934 Act Regulations”).


 


(ii)
Accurate Disclosure. Neither the Registration Statement nor any amendment thereto, at its effective time, or at the Closing
Date, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, neither
(A) the General Disclosure Package nor (B) any individual Issuer Limited Use Free Writing Prospectus, when considered together
with the General Disclosure Package, included an untrue statement of a material fact or omitted to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. Neither
the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its date, at the time of any
filing with the Commission pursuant to Rule 424(b), or at the Closing Date, included, includes or will include an untrue statement
of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. The documents incorporated or deemed to be incorporated
by reference in the Registration Statement, the General Disclosure Package and the Prospectus, at the time the Registration Statement
became effective or when such documents incorporated by reference were filed with the Commission, as the case may be, when read
together with the other information in the Registration Statement, the General Disclosure Package, any Limited Use Free Writing
Prospectus or the Prospectus, as the case may be, did not and will not include an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading.


 


The
representations and warranties in this Section 2(a)(ii) shall not apply to statements in or omissions from the Registration Statement
(or any amendment thereto), the General Disclosure Package, the Prospectus (or any amendment or supplement thereto) or any Issuer
Free Writing Prospectus made in reliance upon and in conformity with written information furnished to the Company by the Placement
Agent expressly for use therein. For purposes of this Agreement, the only information so furnished shall be the statements contained
in the paragraph under the heading “Plan of Distribution” in the section of the Prospectus (collectively, the “Placement
Agent’s Information”).


 




    	 	5	 



    	 



    

 


(iii)
Issuer Free Writing Prospectuses. No Issuer Free Writing Prospectus will be used in connection with the Offering.


 


As
used in this Section 2 and elsewhere in this Agreement:


 


“Applicable
Time” means 8:00 a.m., New York City time, on the date of this Agreement or such other time as agreed by the Company
and the Placement Agent.


 


“General
Disclosure Package” means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable
Time, the most recent preliminary prospectus that is distributed to prospective purchasers prior to the Applicable Time and the
information included on Schedule A hereto, all considered together.


 


“Issuer
Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the 1933
Act Regulations (“Rule 433”), including, without limitation, any “free writing prospectus”
(as defined in Rule 405 of the 1933 Act Regulations (“Rule 405”)) relating to the Securities that is
(i) required to be filed with the Commission by the Company, (ii) a “road show that is a written communication” within
the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from filing with the
Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the Offering that does not
reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be
filed, in the form retained in the Company’s records pursuant to Rule 433(g).


 


“Issuer
General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution
to prospective purchasers (other than a “bona fide electronic road show,” as defined in Rule 433 (the “Bona
Fide Electronic Road Show”)), as evidenced by its being specified in Schedule B hereto.


 


“Issuer
Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use
Free Writing Prospectus.


 


All
references in this Agreement to financial statements and schedules and other information which is “contained,” “included”
or “stated” (or other references of like import) in the Registration Statement, any preliminary prospectus or the
Prospectus shall be deemed to include all such financial statements and schedules and other information incorporated or deemed
incorporated by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the case may be, prior
to the execution and delivery of this Agreement; and all references in this Agreement to amendments or supplements to the Registration
Statement, any preliminary prospectus or the Prospectus shall be deemed to include the filing of any document under the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the “1934 Act”),
incorporated or deemed to be incorporated by reference in the Registration Statement, any preliminary prospectus or the Prospectus,
as the case may be, at or after the execution and delivery of this Agreement.


 


(iv)
Intentionally omitted.


 




    	 	6	 



    	 



    

 


(v)
Independent Accountants. EisnerAmper LLP, who certified financial statements and supporting schedules incorporated by reference
in the Registration Statement, the General Disclosure Package and the Prospectus, are independent public accountants as required
by the 1933 Act, the 1933 Act Regulations and the Public Company Accounting Oversight Board.


 


(vi)
Financial Statements; Non-GAAP Financial Measures. The financial statements included in the Registration Statement, the
General Disclosure Package and the Prospectus, together with the related schedules and notes, present fairly, in all material
respects, the financial position of the Company and its subsidiaries, at the dates indicated and its results of operations, stockholders’
equity and cash flows for the periods specified; said financial statements have been prepared in conformity with U.S. generally
accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods involved
(except for any preparation of non-GAAP measures). The supporting schedules, if any, present fairly, in all material respects,
in accordance with GAAP the information required to be stated therein. The pro forma financial information and the related notes
thereto included or incorporated by reference in each of the Registration Statement, the General Disclosure Package and the Prospectus
has been prepared in accordance with the Commission’s rules and guidance with respect to pro forma financial information,
and the assumptions underlying such pro forma financial information are reasonable and are set forth in each of the Registration
Statement, the General Disclosure Package and the Prospectus. Except as included therein, no other historical or pro forma financial
statements or supporting schedules are required to be included in the Registration Statement, the General Disclosure Package or
the Prospectus under the 1933 Act or the 1933 Act Regulations.


 


(vii)
No Material Adverse Change in Business. Except as otherwise stated therein, since the respective dates as of which information
is given in the Registration Statement, the General Disclosure Package or the Prospectus, (A) there has been no material adverse
change in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Company or
any of its subsidiaries, whether or not arising in the ordinary course of business (a “Material Adverse Effect”),
(B) there have been no transactions entered into by the Company or any of its subsidiaries, other than those in the ordinary course
of business, which are material to the Company, and (C) there has been no dividend or distribution of any kind declared, paid
or made by the Company or any of its subsidiaries on any class of its capital stock.


 


(viii)
Good Standing of the Company. The Company is a corporation duly organized, validly existing and in good standing under
the laws of the State of Delaware. The Company has requisite corporate power and authority to own, lease and operate its properties
and to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and
to enter into and perform its obligations under this Agreement; and the Company is duly qualified as a foreign corporation to
transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason
of the ownership or leasing of property or the conduct of business, except where the failure so to qualify or to be in good standing
would not result in a Material Adverse Effect.


 




    	 	7	 



    	 



    

 


(ix)
Subsidiaries. Each of the Company’s subsidiaries has been duly organized and is validly existing as a corporation
or other entity in good standing under the laws of its jurisdiction of organization, with requisite power and authority to own
or lease its properties and conduct its business as described in the Registration Statement, the General Disclosure Package and
the Prospectus. Each of the Company’s subsidiaries is duly qualified to transact business in all jurisdictions in which
the conduct of its business requires such qualification, except where the failure to be so qualified would not have a Material
Adverse Effect. All of the issued shares of capital stock or other ownership interest of each of the subsidiaries have been duly
authorized and validly issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and
clear of all liens, encumbrances, equities or claims, except for such liens, encumbrances, equities or claims as would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company does not own or control, directly or
indirectly, any corporation, association or other entity other than the subsidiaries listed in Schedule D hereto (each,
a “subsidiary,” and collectively, the “subsidiaries”).


 


(x)
Contracts Affecting Capital. There are no transactions, arrangements or other relationships between and/or among the Company,
any of its affiliates (as such term is defined in Rule 405 of the 1933 Act Regulations) and any unconsolidated entity, including,
but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected to materially
affect the Company’s or its subsidiaries’ liquidity or the availability of or requirements for their capital resources
required to be described or incorporated by reference in the Registration Statement, the General Disclosure Package and the Prospectus
which have not been described or incorporated by reference as required.


 


(xi)
Loans to Directors or Officers. There are no outstanding loans, advances (except normal advances for business expenses
in the ordinary course of business) or guarantees or indebtedness by the Company or its subsidiaries to or for the benefit of
any of the officers or directors of the Company, its subsidiaries or any of their respective family members, except as disclosed
in the Registration Statement, the General Disclosure Package and the Prospectus.


 


(xii)
Smaller Reporting Company; Emerging Growth Company. As of the time of the initial filing of the Registration Statement,
the Company was a “smaller reporting company,” as defined in Rule 12b-2 of the 1934 Act Regulations. As of the date
of this Agreement, the Company is an “emerging growth company,” as defined in Rule 12b-2 of the 1934 Act Regulations.


 


(xiii)
Capitalization. The Company has an authorized capitalization as set forth in the Registration Statement, the General Disclosure
Package and the Prospectus as of the date or dates set forth therein. The outstanding shares of capital stock of the Company have
been duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares of capital stock
of the Company were issued in violation of the preemptive or other similar rights of any securityholder of the Company. Except
as described in or expressly contemplated by the Registration Statement, the General Disclosure Package and the Prospectus, there
are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments
convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company, or any contract, commitment,
agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company, any such convertible
or exchangeable securities or any such rights, warrants or options.


 




    	 	8	 



    	 



    

 


(xiv)
Stock Options. With respect to the outstanding stock options (the “Stock Options”)
granted pursuant to the stock-based compensation plans of the Company (the “Company Stock Plans”), (i)
each Stock Option intended to qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code
of 1986, as amended (the “Code”), so qualified, (ii) each grant of a Stock Option was duly authorized
no later than the date on which the grant of such Stock Option was by its terms to be effective (the “Grant Date”)
by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted
and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents,
and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant
was made in accordance with the terms of the Company Stock Plans and all other applicable laws and regulatory rules or requirements,
except where the failure to comply with such laws, regulatory rules or requirements would not result in a Material Adverse Effect,
and (iv) each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related
notes) of the Company included in the Registration Statement, the General Disclosure Package and the Prospectus, to the extent
required under GAAP to be accounted for in such financial statements.


 


(xv)
Authorization of Agreements. This Agreement and the Placement Agent’s Warrant Agreement have been duly authorized,
executed and delivered by the Company.


 


(xvi)
Authorization of Certificate of Designation. The Certificate of Designation, the proposed form of which has been furnished
to you, has been duly authorized by the Company and will have been duly executed and delivered by the Company and duly filed with
the Secretary of State of the State of Delaware before the Closing Date. The holders of the Series B Preferred Stock will have
the rights set forth in the Certificate of Designation upon filing of the Certificate of Designation with the Secretary of State
of the State of Delaware.


 


(xvii)
Authorization and Description of Securities. The Shares to be purchased by the Purchasers from the Company and the Placement
Agent’s Securities to be purchased by the Placement Agent from the Company have been duly authorized for issuance and sale
to the Purchasers and the Placement Agent pursuant to this Agreement and, when issued and delivered by the Company pursuant to
this Agreement against payment of the consideration set forth herein, will be duly and validly issued, fully paid and non-assessable
and will have the rights, preferences and priorities set forth in the Company’s Certificate of Incorporation (including
the Certificate of Designation). The Conversion Shares have been duly authorized and reserved for issuance pursuant to the terms
of the Shares, and when issued by the Company upon valid conversion of the Shares, will be duly and validly issued, fully paid
and nonassessable. The Dividend Shares have been duly authorized and reserved for issuance pursuant to the terms of the Shares,
and when issued by the Company in payment of dividends on the Shares, will be duly and validly issued, fully paid and nonassessable.
The Warrant Shares have been duly authorized and reserved for issuance and when issued by the Company pursuant to the terms of
the Placement Agent’s Warrant Agreement, will be duly and validly issued, fully paid and nonassessable. The issuance of
the Shares, Conversion Shares, Dividend Shares and Placement Agent’s Securities is not subject to any preemptive or other
similar rights of any securityholder of the Company other than those rights that have been disclosed in the Registration Statement,
the General Disclosure Package and the Prospectus and have been waived. The capital stock of the Company conforms in all material
respects to all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus.
No holder of Securities or the Placement Agent’s Securities will be subject to personal liability solely by reason of being
such a holder.


 




    	 	9	 



    	 



    

 


(xviii)
Registration Rights. There are no persons with registration rights or other similar rights to have any securities registered
for sale pursuant to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act, other
than those rights that have been disclosed in the Registration Statement, the General Disclosure Package and the Prospectus and
have been waived or satisfied.


 


(xix)
Absence of Violations, Defaults and Conflicts. The Company and each of its subsidiaries is not (A) in violation of its
charter or by-laws or other applicable organizational or governing documents, (B) in default in the performance or observance
of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or credit
agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which
it may be bound or to which any of the properties or assets of the Company or any of its subsidiaries is subject (collectively,
“Agreements and Instruments”), except for such defaults that would not reasonably be expected to, singly
or in the aggregate, result in a Material Adverse Effect, or (C) in violation of any law, statute, rule, regulation, judgment,
order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency or other authority,
body or agency having jurisdiction over the Company, any of its subsidiaries or any of their respective properties, assets or
operations (each, a “Governmental Entity”), except for such violations that would not reasonably be
expected to, singly or in the aggregate, result in a Material Adverse Effect. The execution, delivery and performance of this
Agreement, the Placement Agent’s Warrant Agreement and the consummation of the transactions contemplated herein and therein
and in the Registration Statement, the General Disclosure Package and the Prospectus (including the issuance and sale of the Securities
and the use of the proceeds from the sale of the Securities as described therein under the caption “Use of Proceeds”
in the Prospectus) and compliance by the Company with its obligations hereunder and under the Placement Agent’s Warrant
Agreement and the Certificate of Designation have been duly authorized by all necessary corporate action and do not and will not,
whether with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or
Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any
properties or assets of the Company or any of its subsidiaries pursuant to, the Agreements and Instruments (except for such conflicts,
breaches, defaults or Repayment Events or liens, charges or encumbrances that would not reasonably be expected to, singly or in
the aggregate, result in a Material Adverse Effect), nor will such action result in any violation of (i) the provisions of the
charter, by-laws or similar organization or governing document of the Company or any of its subsidiaries or (ii) any law, statute,
rule, regulation, judgment, order, writ or decree of any Governmental Entity, except with respect to clause (ii), such violations
as would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. As used herein, a “Repayment
Event” means any event or condition which gives the holder of any note, debenture or other evidence of indebtedness
(or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a
portion of such indebtedness by the Company or any of its subsidiaries.


 




    	 	10	 



    	 



    

 


(xx)
Absence of Labor Dispute. No labor dispute with the employees of the Company or any of its subsidiaries exists or, to the
knowledge of the Company, is threatened, and the Company has no knowledge of any existing or imminent labor dispute by the employees
of any of its principal suppliers, manufacturers, customers or contractors.


 


(xxi)
Absence of Proceedings. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus,
there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to
the knowledge of the Company, threatened against the Company or any of its subsidiaries, which would reasonably be expected to,
singly or in the aggregate, result in a Material Adverse Effect, or which would reasonably be expected to, singly or in the aggregate,
materially and adversely affect the consummation of the transactions contemplated in this Agreement or the performance by the
Company of its obligations hereunder.


 


(xxii)
Accuracy of Exhibits. There are no contracts or documents which are required to be described in the Registration Statement,
the General Disclosure Package or the Prospectus or to be filed as exhibits to the Registration Statement which have not been
so described and filed as required.


 


(xxiii)
Absence of Further Requirements. No filing with, or authorization, approval, consent, license, order, registration, qualification
or decree of, any Governmental Entity is necessary or required for the performance by the Company of its obligations hereunder,
in connection with the offering, issuance or sale of the Securities hereunder or the consummation of the transactions contemplated
by this Agreement and as contemplated in the Registration Statement, the General Disclosure Package and the Prospectus, except
such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the 1934 Act, the 1934
Act Regulations, the rules of the NYSE American (the “Exchange”) or state securities laws.


 




    	 	11	 



    	 



    

 


(xxiv)
Possession of Licenses and Permits. The Company and each of its subsidiaries possesses such permits, licenses, certificates,
approvals, clearances, consents and other authorizations (collectively, “Governmental Licenses”) issued
by the appropriate Governmental Entities necessary to conduct the business now operated by them, except where the failure so to
possess would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. The Company and
each of its subsidiaries is in compliance with the terms and conditions of all Governmental Licenses and, to the Company’s
knowledge, no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof
or result in any other material impairment of the rights of the holder of any Government License, except where the failure so
to comply would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental
Licenses are valid and in full force and effect. Neither the Company nor any of its subsidiaries (a) has received notice of any
ongoing claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any U.S. or non-U.S.
Governmental Entity or third party alleging that any product, operation or activity is in violation of any Governmental Licenses
and has no knowledge that any such Governmental Entity or third party is considering any such claim, litigation, arbitration,
action, suit, investigation or proceeding; (b) has received notice that any Governmental Entity has taken, is taking or intends
to take regulatory action, and has no knowledge that any Governmental Entity is considering such action; and (c) is a party to
any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, or
similar agreements, or has any reporting obligations pursuant to any such agreement, plan or correction or other remedial measure
entered into with any Governmental Entity.


 


(xxv)
Title to Property. The Company and each of its subsidiaries has good and marketable title to all real property owned by
it and good title or valid leases to all personal property owned by it, in each case, free and clear of all mortgages, pledges,
liens, security interests, claims, restrictions or encumbrances (except for customary easements and rights of way) of any kind
except such as (A) are described in the Registration Statement, the General Disclosure Package and the Prospectus or (B) do not,
singly or in the aggregate, materially affect the value of such property and do not materially interfere with the use made and
proposed to be made of such property by the Company and its subsidiaries; and all of the leases and subleases material to the
business of the Company and that of its subsidiaries and under which the Company or any of its subsidiaries holds properties described
in the Registration Statement, the General Disclosure Package or the Prospectus, are in full force and effect, and neither the
Company nor any of its subsidiaries has received any written notice of any material claim of any sort that has been asserted by
anyone adverse to the rights of the Company or any of its subsidiaries under any of the leases or subleases mentioned above, or
affecting or questioning the rights of the Company or any of its subsidiaries to the continued possession of the leased or subleased
premises under any such lease or sublease.


 


(xxvi)
Possession of Intellectual Property. Except as would not reasonably be expected to have a Material Adverse Effect, (i)
the Company and each of its subsidiaries owns all right, title and interest in or otherwise have the right to use all patents,
inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures), trademarks, service marks, trade names and other intellectual property rights (collectively,
“Intellectual Property”) that is necessary for, used or held for use in, or otherwise exploited in connection
with, the conduct of the business now operated by them and as proposed to be operated, and (ii) to the Company’s knowledge,
neither the Company nor any of its subsidiaries is infringing, misappropriating, diluting or otherwise violating the Intellectual
Property of any third party. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus
or as would not reasonably be expected to have a Material Adverse Effect, (i) no action, suit, claim, or other proceeding is pending,
or to the Company’s knowledge, is threatened, alleging that the Company or any of its subsidiaries is infringing, misappropriating,
diluting, or otherwise violating the Intellectual Property of any third party in any respect, and (ii) no action, suit, claim,
or other proceeding is pending, or to the Company’s knowledge, is threatened, challenging the validity, enforceability,
scope, registration, ownership or use of any Intellectual Property of the Company or any of its subsidiaries that is, singly or
in the aggregate, necessary to its business (with the exception of office actions in connection with applications for the registration
or issuance of such Intellectual Property).


 




    	 	12	 



    	 



    

 


(xxvii)
Environmental Laws. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus
or would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect, (A) neither the Company
nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance,
code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative
order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation,
ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and
regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous
substances, petroleum or petroleum products, asbestos-containing materials or mold (collectively, “Hazardous Materials”)
or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials
(collectively, “Environmental Laws”), (B) the Company and each of its subsidiaries has all permits,
authorizations and approvals required under any applicable Environmental Laws and is in compliance with their requirements, (C)
there are no pending or, to the knowledge of the Company, threatened administrative, regulatory or judicial actions, suits, demands,
demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental
Law against the Company or any of its subsidiaries and (D) to the knowledge of the Company, there are no existing events, conditions
or facts that would reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding
by any private party or Governmental Entity, against or affecting the Company or any of its subsidiaries relating to Hazardous
Materials or any Environmental Laws.


 


(xxviii)
Disclosure Controls. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus,
the Company maintains an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of
the 1934 Act) that complies with the requirements of the 1934 Act and that has been designed to ensure that information required
to be disclosed by the Company in reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported
within the time periods specified in the Commission’s rules and forms, including controls and procedures designed to ensure
that such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions
regarding required disclosure.


 




    	 	13	 



    	 



    

 


(xxix)
Accounting Controls. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus,
the Company maintains effective internal control over financial reporting (as defined under Rule 13a-15 and 15d-15 of the 1934
Act Regulations) and a system of internal accounting controls sufficient to provide reasonable assurances that (A) transactions
are executed in accordance with management’s general or specific authorization; (B) transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C) access to
assets is permitted only in accordance with management’s general or specific authorization; (D) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences
and (E) the interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement,
the General Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared
in accordance with the Commission’s rules and guidelines applicable thereto. Except as described in the Registration Statement,
the General Disclosure Package and the Prospectus, since the end of the Company’s most recent audited fiscal year, there
has been (1) no material weakness in the Company’s internal control over financial reporting (whether or not remediated)
and (2) no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably
likely to materially affect, the Company’s internal control over financial reporting.


 


(xxx)
Payment of Taxes. All United States federal income tax returns of the Company and each of its subsidiaries required by
law to be filed have been filed and all taxes shown by such returns or otherwise assessed, which are due and payable, have been
paid, except assessments against which appeals have been or will be promptly taken and as to which adequate reserves have been
provided other than as would not reasonably be expected to, singly or in the aggregate, have a Material Adverse Effect. The Company
and each of its subsidiaries has filed all other tax returns that are required to have been filed by them pursuant to applicable
foreign, state, local or other law except insofar as the failure to file such returns would not result in a Material Adverse Effect,
and have paid all taxes due pursuant to such returns or pursuant to any assessment received by the Company or any such subsidiary,
except for such taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by
the Company or any such subsidiary, other than as would not reasonably be expected to, singly or in the aggregate, have a Material
Adverse Effect. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the charges,
accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally
determined are believed to be adequate to meet any assessments or re-assessments for additional income tax for any years not finally
determined, except to the extent of any inadequacy that would not reasonably be expected to result in a Material Adverse Effect.


 




    	 	14	 



    	 



    

 


(xxxi)
Insurance. The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and
covering such risks as is reasonably prudent and customary in the businesses in which it is engaged, and all such insurance is
in full force and effect. The Company has no reason to believe that it will not be able (A) to renew its existing insurance coverage
as and when such policies expire or (B) to obtain comparable coverage from similar institutions as may be necessary or appropriate
to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. The Company has not
been denied the issuance of any material insurance policies which it has sought or for which it has applied in the prior three
years, except for any applications still pending.


 


(xxxii)
Investment Company Act. The Company is not required, and upon the issuance and sale of the Securities as herein contemplated
and the application of the net proceeds therefrom as described in the Registration Statement, the General Disclosure Package and
the Prospectus will not be required, to register as an “investment company” under the Investment Company Act of 1940,
as amended (the “1940 Act”).


 


(xxxiii)
Absence of Manipulation. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any affiliate
take, directly or indirectly, any action which is designed, or would reasonably be expected, to cause or result in, or which constitutes,
the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities.


 


(xxxiv)
No Integration. The Company has not sold or issued any securities that would be integrated with the Offering pursuant to
the 1933 Act, the 1933 Act Regulations or the interpretations thereof by the Commission.


 


(xxxv)
ERISA. Other than as would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect
and except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, (i) no “employee
benefit plan” (as defined in Section 3(3) of ERISA), for which the Company would have any liability (whether absolute or
contingent) (each a “Plan”) has experienced a failure to satisfy the “minimum funding standard”
(as defined in Section 302 of the Employee Retirement Income Security Act of 1974, as amended, (“ERISA”)
or Section 412 of the Internal Revenue Code of 1986, as amended (the “Code”)), or other event of the
kind described in Section 4043(c) of ERISA (other than events with respect to which the 30-day notice requirement under Section
4043 of ERISA has been waived) or any similar minimum funding failure event with respect to any Plan (other than a Plan that under
applicable law is required to be funded by a trust or funding vehicle maintained exclusively by a governmental authority) that
is maintained outside of the United States primarily for the benefit of persons substantially all of whom are nonresident aliens
(ii) each Plan is in compliance in all respects with applicable law, including, without limitation, ERISA and the Code; (iii)
other than in the ordinary course, neither the Company nor any trade or business, whether or not incorporated, that, together
with the Company, would be deemed to be a “single employer” within the meaning of Section 4001(b)(1) of ERISA or Section
414(b), 414(c), 414(m) or 414(o) of the Code has incurred or reasonably expects to incur any liability with respect to any Plan
(A) under Title IV of ERISA or (B) in respect of any post-employment health, medical or life insurance benefits for former, current
or future employees of the Company, except as required to avoid excise tax under Section 4980B of the Code and except, on a case
by case basis, limited extensions of health insurance benefits (for a period of no more than 18 months post-employment) to former
employees receiving severance payments from the Company; and (iv) each Plan that is intended to be qualified under Section 401(a)
of the Code is so qualified and nothing has occurred, whether by action or by failure to act, which could cause the loss of such
qualification. The Company is not, nor at any time during the last three years has the Company been, a party to any collective
bargaining agreement or other labor agreement with respect to employees of the Company. There are no pending, or, to the Company’s
knowledge, threatened, activities or proceedings by any labor union or similar entity to organize any employees of the Company.
No labor dispute with, or labor strike, work stoppage or other material labor disturbance by, the employees of the Company exists
or to the Company’s knowledge is imminent.


 




    	 	15	 



    	 



    

 


(xxxvi)
Foreign Corrupt Practices Act. Neither the Company, any of its subsidiaries nor, to the knowledge of the Company, any director,
officer, agent, employee, affiliate or other person acting on behalf of the Company has taken any action, directly or indirectly,
that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations
thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality
of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money,
or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official”
(as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political
office, in contravention of the FCPA and the Company, its subsidiaries and, to the knowledge of the Company, its and their respective
affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain policies and procedures
designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.


 


(xxxvii)
Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related
or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money
Laundering Laws”); and no action, suit or proceeding by or before any Governmental Entity involving the Company
or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.


 




    	 	16	 



    	 



    

 


(xxxviii)
OFAC. Neither the Company, any of its subsidiaries nor, to the knowledge of the Company, its or their respective directors,
officers, agents, employees, affiliates or Placement Agents (each, a “Person” ) are currently the subject
of sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department of the
Treasury’s Office of Foreign Assets Control (“OFAC”), the United Nations Security Council, the
European Union, Her Majesty’s Treasury, or other relevant sanctions authority applicable to the Company and its subsidiaries
(collectively, “Sanctions”), nor is the Company or any of its subsidiaries located, organized or resident
in a country or territory that is the subject of Sanctions; and the Company does not intend to, directly or indirectly, use the
proceeds of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint
venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that,
at the time of such funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person
(including any Person participating in the transaction, whether as underwriter, advisor, purchaser or otherwise) of Sanctions.


 


(xxxix)
Lending Relationship. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus,
the Company (A) does not have any material lending or other relationship with any bank or lending affiliate of any underwriter
and (B) does not intend to use any of the proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate
of any underwriter.


 


(xl)
Statistical and Market-Related Data. Any statistical and market-related data included in the Registration Statement, the
General Disclosure Package or the Prospectus are based on or derived from sources that the Company believes, after reasonable
inquiry, to be reliable and accurate in all material respects and, to the extent required, the Company has obtained the written
consent to the use of such data from such sources.


 


(xli)
Accuracy of Descriptions. The statements set forth in the Registration Statement, the General Disclosure Package and the
Prospectus under the captions “Description of the Securities We Are Offering” and “Description of Capital Stock,”
insofar as they purport to constitute a summary of the terms of the Series A Preferred Stock of the Company, the Series B Preferred
Stock and the Common Stock (including the Conversion Shares, the Dividend Shares and the Warrant Shares) are accurate, complete
and fair summaries in all material respects.


 


(xlii)
Stock Exchange Listing. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the 1934 Act and is listed
on the Exchange; the Company has taken no action designed to, or likely to have the effect of, terminating the registration of
the Common Stock under the 1934 Act or delisting the Common Stock from the Exchange; the Company has not received any notice that
it is out of compliance with the listing or maintenance requirements of the Exchange and the Company is, and will continue to
be, in material compliance with all such listing and maintenance requirements; and the Company has not received any notification
that the Commission or the Exchange is contemplating terminating the registration of the Common Stock under the 1934 Act or delisting
the Common Stock from the Exchange.


 


(xliii)
Maintenance of Rating. The Company does not have any securities rated by any “nationally recognized statistical rating
organization” (as defined for purposes of Rule 436(g) under the 1933 Act).


 


(xliv)
Related Party Transactions. There are no business relationships or related-party transactions involving the Company, any
of its subsidiaries or any other person required to be described in the Registration Statement, any preliminary prospectus, the
Prospectus and the General Disclosure Package which have not been described as required. The General Disclosure Package contains
in all material respects the same description of the matters set forth in the preceding sentence contained in the Prospectus.


 




    	 	17	 



    	 



    

 


(xlv)
Board of Directors. At least one member of the Audit Committee of the Board of Directors of the Company qualifies as an
“audit committee financial expert,” as such term is defined under Regulation S-K and the listing rules of the Exchange.
In addition, at least a majority of the persons serving on the Board of Directors qualify as “independent,” as defined
under the listing rules of the Exchange.


 


(xlvi)
Brokers. Except for the Placement Agent commissions payable to the Placement Agent as described in the Registration Statement,
the General Disclosure Package and the Prospectus, there is no broker, finder or other party that is entitled to receive from
the Company any brokerage or finder’s fee or other fee or commission as a result of any transactions contemplated by this
Agreement.


 


(xlvii)
Margin Rules and Securities. The application of the proceeds received by the Company from the issuance, sale and delivery
of the Securities as described in the Registration Statement, the General Disclosure Package and the Prospectus will not violate
Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.
Further, the Company owns no “margin securities” as that term is defined in Regulation U of the Board of Governors,
and none of the proceeds of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin
security, for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin
security or for any other purpose which might cause any of the shares of Common Stock to be considered a “purpose credit”
within the meanings of Regulation T, U or X of the Federal Reserve Board.


 


(xlviii)
Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the 1933 Act) contained
in the Registration Statement, the General Disclosure Package or the Prospectus has been made or reaffirmed by the Company without
a reasonable basis or has been disclosed by the Company other than in good faith.


 


(xlix)
Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or, to the knowledge of the Company, any
of the Company’s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley
Act and the rules and regulations promulgated in connection therewith, including Section 402 related to loans.


 


(l)
Lock-Up Agreements. Schedule C hereto contains a complete and accurate list of the Company’s officers, directors
and certain key stockholders (collectively, the “Lock-Up Parties”). The Company has caused each of the
Lock-Up Parties to deliver to the Placement Agent an executed Lock-Up Agreement, in the form attached hereto as Exhibit B
(the “Lock-Up Agreement”), prior to the execution of this Agreement.


 




    	 	18	 



    	 



    

 


(li)
Transactions Affecting Disclosure to FINRA.


 


	 	a.	FINRA
    Affiliation. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there
    are no affiliations or associations between any member of FINRA and any of the Company’s officers, directors or 5% or
    greater securityholders (“Insiders”).
	 	 	 
	 	b.	Finder’s
    Fees. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus, there are
    no claims, payments, arrangements, agreements or understandings relating to the payment of a finder’s, consulting or
    origination fee by the Company or any Insider with respect to the sale of the Securities hereunder or any other arrangements,
    agreements or understandings of the Company or, to the Company’s knowledge, any of its shareholders that may affect
    the Placement Agent’s compensation, as determined by FINRA.
	 	 	 
	 	c.	Payments
    Within Twelve (12) Months. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus,
    the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder’s
    fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company
    persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii) any person or entity that has any direct
    or indirect affiliation or association with any FINRA member, within the twelve (12) months prior to the Closing Date, other
    than the payment to the Placement Agent as provided hereunder in connection with the Offering.
	 	 	 
	 	d.	Use
    of Proceeds. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or
    its affiliates, except as specifically authorized herein.
	 	 	 
	 	e.	Information.
    All information provided by the Company in its FINRA questionnaire to Placement Agent Counsel, as such term is defined below,
    specifically for use by Placement Agent Counsel in connection with its Public Offering System filings (and related disclosure)
    with FINRA is true, correct and complete in all material respects.


 


(b)
Officer’s Certificates. Any certificate signed by any officer of the Company delivered to the Placement Agent or
Placement Agent Counsel shall be deemed a representation and warranty by the Company (and not by such officer in his or her personal
capacity) to the Placement Agent and the Purchasers as to the matters covered thereby.


 




    	 	19	 



    	 



    

 


SECTION
3. Covenants of the Company. The Company covenants with the Placement Agent and the Purchasers as follows:


 


(a)
Compliance with Securities Regulations and Commission Requests. The Company, subject to Section 3(b) hereof, will comply
with the requirements of Rule 430B, and will notify the Placement Agent promptly, and confirm the notice in writing, (i) when
any post-effective amendment to the Registration Statement shall have been filed or been declared effective or any amendment or
supplement to the Prospectus, shall have been filed or distributed, (ii) of the receipt of any comments from the Commission, (iii)
of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus,
including any document incorporated or deemed to be incorporated by reference therein, or for additional information, including,
but not limited to, any request for information concerning any oral or written communication with potential purchasers and undertaken
in reliance on Section 5(d) of the 1933 Act, (iv) of the issuance by the Commission of any stop order suspending the effectiveness
of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any preliminary
prospectus, the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction,
or of the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d)
or 8(e) of the 1933 Act concerning the Registration Statement, (v) of the occurrence of any event or development at any time
when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172 of the 1933 Act Regulations (“Rule
172”), would be) required by the 1933 Act to be delivered in connection with sales of the Securities (the “Prospectus
Delivery Period”) as a result of which the Prospectus, the General Disclosure Package, as then amended or supplemented
would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances existing when the Prospectus, the General Disclosure Package, is delivered to a purchaser,
not misleading; and (vi) if the Company becomes the subject of a proceeding under Section 8A of the 1933 Act in connection with
the Offering. The Company will effect all filings required under Rule 424(b), in the manner and within the time period required
by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it deems necessary to ascertain promptly whether
the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that
it was not, it will promptly file such prospectus. The Company will use commercially reasonable efforts to prevent the issuance
of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any preliminary
prospectus, the Prospectus or suspending any such qualification of the Securities and, if any such order is issued, will use commercially
reasonable efforts to obtain as soon as possible the withdrawal thereof.


 


(b)
Continued Compliance with Securities Laws. The Company will comply with the 1933 Act and the 1933 Act Regulations during
the Prospectus Delivery Period so as to permit the completion of the distribution of the Securities as contemplated in this Agreement
and in the Registration Statement, the General Disclosure Package and the Prospectus. If at any time during the Prospectus Delivery
Period any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the
Placement Agent or for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not
include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus in order
that the General Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances
existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the General
Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the 1933 Act or the 1933
Act Regulations, the Company will promptly (A) give the Placement Agent notice of such event, (B) prepare any amendment or supplement
as may be necessary to correct such statement or omission or to make the Registration Statement, the General Disclosure Package
or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish
the Placement Agent with copies of any such amendment or supplement and (C) file with the Commission any such amendment or supplement;
provided that the Company shall not file or use any such amendment or supplement to which the Placement Agent or counsel
for the Placement Agent shall reasonably object unless the Company reasonably believes that the failure to file or use such amendment
or supplement would constitute a violation of law or subject it to liability. The Company will furnish to the Placement Agent
such number of copies of such amendment or supplement as the Placement Agent may reasonably request. The Company has given the
Placement Agent notice of any filings made pursuant to the 1934 Act or 1934 Act Regulations within 48 hours prior to the Applicable
Time; the Company will give the Placement Agent notice of its intention to make any such filing from the Applicable Time to the
Closing Date and will furnish the Placement Agent with copies of any such documents a reasonable amount of time prior to such
proposed filing, as the case may be, and will not file or use any such document to which the Placement Agent or counsel for the
Placement Agent shall reasonably object unless the Company reasonably believes that the failure to file or use such amendment
or supplement would constitute a violation of law or subject it to liability.


 




    	 	20	 



    	 



    

 


(c)
The Company will not, and will cause its affiliated purchasers (as defined in Regulation M under the 1934 Act) not to, either
alone or with one or more other persons, bid for or purchase, for any account in which it or any of its affiliated purchasers
has a beneficial interest, any Shares, or attempt to induce any person to purchase any Shares; and not to, and to cause its affiliated
purchasers not to, make bids or purchase for the purpose of creating actual, or apparent, active trading in or of raising the
price of the Shares; provided, however, that this clause (c) shall not affect the ability of the Company’s affiliated purchasers
to purchase Shares in the Offering.


 


(d)
Delivery of Registration Statements. The Company has furnished or will deliver to the Placement Agent and to counsel for
the Placement Agent, without charge, signed copies of the Registration Statement as originally filed and each amendment thereto
(including exhibits filed therewith) and signed copies of all consents and certificates of experts, and will also deliver to the
Placement Agent, without charge, a conformed copy of the Registration Statement as originally filed and each amendment thereto
(without exhibits). The copies of the Registration Statement and each amendment thereto furnished to the Placement Agent will
be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent
permitted by Regulation S-T.


 


(e)
Delivery of Prospectuses. The Company has delivered to the Placement Agent, without charge, as many copies of each preliminary
prospectus as the Placement Agent may reasonably request, and the Company hereby consents to the use of such copies for purposes
permitted by the 1933 Act. The Company will furnish to the Placement Agent, without charge, during the Prospectus Delivery Period,
such number of copies of the Prospectus (as amended or supplemented) as the Placement Agent may reasonably request. The Prospectus
and any amendments or supplements thereto furnished to the Placement Agent will be identical to the electronically transmitted
copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.


 




    	 	21	 



    	 



    

 


(f)
Blue Sky Qualifications. The Company will use its commercially reasonable efforts, in cooperation with the Placement Agent,
to qualify the Securities for offering and sale under the applicable securities laws of such states and other jurisdictions (domestic
or foreign) as the Placement Agent may designate and to maintain such qualifications in effect so long as required to complete
the distribution of the Securities; provided, however, that the Company shall not be obligated to file any general
consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which
it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise
so subject.


 


(g)
Rule 158. The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally
available to its securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Placement
Agent the benefits contemplated by, the last paragraph of Section 11(a) of the 1933 Act.


 


(h)
Use of Proceeds. The Company will use the net proceeds received by it from the sale of the Securities in the manner specified
in the Registration Statement, the General Disclosure Package and the Prospectus under “Use of Proceeds.”


 


(i)
Effective Registration; Listing. The Company will use its reasonable best efforts to cause the Conversion Shares and the
Dividend Shares to continue to be registered under the 1933 Act for the periods set forth in the Certificate of Designation; provided
however that the Company shall have no obligation to register such Conversion Shares or Dividend Shares to the extent an exemption
from registration is available under Section 3(a)(9) of the Securities Act and such shares may be resold without restriction under
the Securities Act or such shares may be issued without legend and resold without restriction under Rule 144 promulgated by the
Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule (“Rule
144”). The Warrant Shares shall be included in any registration statements filed in connection with the preceding
sentence provided however that the Company shall have no obligation to register such Warrant Shares to the extent an exemption
from registration is available under Section 3(a)(9) of the Securities Act and such shares may be resold without restriction under
the Securities Act or such shares may be issued without legend and resold without restriction under Rule 144. The Company will
use its commercially reasonable efforts to cause the Conversion Shares, the Dividend Shares and the Warrant Shares to be included
on the Exchange, subject to notice of issuance, and to maintain the listing of the Common Stock on the Exchange.



 




    	 	22	 



    	 



    

 


(j)
Company Lock-Up Agreements.


 


(i)
Restrictions on Sales of Capital Stock. The Company, on behalf of itself and any successor entity, agrees that, without
the prior written consent of the Placement Agent, it will not, for a period of 90 days after the date of this Agreement (the “Lock-Up
Period”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly,
any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital
stock of the Company; (2) file or caused to be filed any registration statement with the Commission relating to the offering of
any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital
stock of the Company; (3) complete any offering of debt securities of the Company, other than entering into a line of credit with
a traditional bank or (4) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (1), (2),
(3) or (4) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or otherwise.


 


The
restrictions contained in this Section 3(j)(i) shall not apply to (A) the Shares to be sold in the Offering, (B) the issuance
by the Company of the Conversion Shares, the Dividend Shares or the Warrant Shares, (C) the issuance by the Company of shares
of Common Stock upon the exercise of a stock option or warrant or the conversion of, or as payment of a dividend pursuant to the
terms of, a security outstanding on the date hereof, of which the Placement Agent has been advised in writing or as have been
disclosed in the Registration Statement, General Disclosure Package or Prospectus, (D) the issuance by the Company of stock options
or shares of capital stock of the Company under any equity compensation plan of the Company, or (E) the issuance of shares of
Common Stock or other securities in connection with any acquisition, strategic partnership, joint venture or collaboration..


 


(ii)
Restriction on Continuous Offerings. The Company, on behalf of itself and any successor entity, agrees that, without the
prior written consent of the Placement Agent, it will not, for a period of 30 days after the Closing Date, directly or indirectly
in any “at-the-market” or continuous equity transaction, including, without limitation, the Controlled Equity Offering
with Cantor Fitzgerald & Co. (“Cantor”) pursuant to the Sale Agreement, dated April 28, 2017, by
and between the Company and Cantor, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of shares
of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock
of the Company.


 


(k)
Intentionally Omitted.


 


(l)
Intentionally Omitted.


 


(m)
Reservation of Common Stock. The Company shall reserve and keep available at all times a sufficient number of shares of
Common Stock for purpose of enabling the Company to issue the Conversion Shares, the Dividend Shares and Warrant Shares.


 




    	 	23	 



    	 



    

 


(n)
Rule 462(b) Registration Statement. If the Company elects to rely upon Rule 462(b) under the 1933 Act, the Company will
file a Rule 462(b) Registration Statement with the Commission in compliance with Rule 462(b) by 10:00 p.m., Washington, D.C. time,
on the date of this Agreement, and at the time of filing either to pay to the Commission the filing fee for the Rule 462(b) Registration
Statement or to give irrevocable instructions for the payment of such fee pursuant to Rule 111(b) under the 1933 Act.


 


(o)
Intentionally Omitted.


 


(p)
Intentionally Omitted.


 


(q)
Intentionally Omitted. 


 


 (r) No Fiduciary Duties. The Company acknowledges and agrees that:



 


i.
the Placement Agent’s responsibility to the Company is solely contractual in nature and that neither the Placement Agent
or its affiliates or any selling agent shall be deemed to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty
to the Company or any of its affiliates in connection with the Offering and the other transactions contemplated by this Agreement;


 


ii.
the price of the Securities set forth in this Agreement was established by the Company following discussions and arms-length negotiations
with the Placement Agent and the Purchasers, and the Company is capable of evaluating and understanding, and understands and accepts,
the terms, risks and conditions of the transactions contemplated by this Agreement;


 


iii.
it has been advised that the Placement Agent and its affiliates are engaged in a broad range of transactions which may involve
interests that differ from those of the Company and that the Placement Agent has no obligation to disclose such interests and
transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and


 


iv.
it waives, to the fullest extent permitted by law, any claims it may have against the Placement Agent for breach of fiduciary
duty or alleged breach of fiduciary duty and agrees that the Placement Agent shall have no liability (whether direct or indirect)
to the Company in respect of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or in
right of the Company, including stockholders, employees or creditors of the Company.


 


(s)
Transfer Agent. For a period of three (3) years after the date of this Agreement, the Company shall retain a Transfer Agent
and registrar for the Series B Preferred and the common stock.


 


(t)
Intentionally Omitted.


 




    	 	24	 



    	 



    

 


SECTION
4. Payment of Expenses.


 


(a)
General Expenses Related to the Offering. The Company hereby agrees to pay, or reimburse if paid by the Placement Agent:
all expenses incident to the performance of the obligations of the Company under this Agreement, including, but not limited to:
(a) all filing fees and communication expenses relating to the registration of the shares of Series B Preferred Stock to be sold
in the Offering with the Commission; (b) all Public Filing System filing fees associated with the review of the Offering by FINRA;
(c) all fees and expenses relating to the inclusion of the Conversion Shares, the Dividend Shares and the Warrant Shares on the
Exchange; (d) all fees, expenses and disbursements relating to background checks of the Company’s officers and directors
in an amount not to exceed $5,000 in the aggregate; (e) (g) the costs of all mailing and printing of the placement documents (including,
without limitation, the Placement Agency Agreement, any Blue Sky Surveys and, if appropriate, any Agreement Among Underwriters
and Selected Dealers’ Agreement), Registration Statements, Prospectuses and all amendments, supplements and exhibits thereto
and as many preliminary and final Prospectuses as the Placement Agent may reasonably deem necessary; (h) the $29,500 cost associated
with the use of Ipreo’s book building, prospectus tracking and compliance software for the Offering; (i) fees and expenses
of the transfer agent for the Shares; (j) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from
the Company to the Purchasers; (l) the fees and expenses of the Company’s accountants; (m) the fees and expenses of the
Company’s legal counsel and other agents; (n) fees and expenses of Placement Agent Counsel not to exceed $75,000; and (o)
the costs incident to the authorization, issuance, sale, preparation and delivery of the Securities to the Purchasers, and any
taxes payable in that connection.


 


(b)
Non-Accountable Expenses. The Company further agrees that, in addition to the expenses payable pursuant to Section 4(a),
on the Closing Date the Placement Agent shall deduct from the gross proceeds of the Offering contemplated herein, a non-accountable
expense allowance equal to one percent (1%) of the gross proceeds received from the sale of the Shares, less the Advance (as such
term is defined in Section 9(c) hereof), provided, however, that in the event that the Offering is terminated, the Company agrees
to reimburse the Placement Agent pursuant to Section 9(c) hereof.


 


SECTION
5. Conditions of Placement Agent’s Obligations. The obligations of the Placement Agent hereunder are subject to the
accuracy of the representations and warranties of the Company contained herein or in certificates of any officer of the Company
delivered pursuant to the provisions hereof, to the performance by the Company of the covenants and other obligations hereunder,
and to the following further conditions:


 


(a)
Effectiveness of Registration Statement; Rule 430B Information. The Registration Statement, including any Rule 462(b) Registration
Statement, has been declared effective and, at the Closing Date, no stop order suspending the effectiveness of the Registration
Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use
of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted
or are pending or, to the Company’s knowledge, contemplated; and the Company has complied with each request (if any) from
the Commission for additional information to the reasonable satisfaction of counsel to the Company and counsel to the Placement
Agent. A prospectus containing the Rule 430B Information shall have been filed with the Commission in the manner and within the
time frame required by Rule 424(b) without reliance on Rule 424(b)(8) or a post-effective amendment providing such information
shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430B.


 




    	 	25	 



    	 



    

 


(b)
No Untrue Statements. The Placement Agent shall not have discovered and disclosed to the Company on or prior to the Closing
Date that the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact which, in the
opinion of Placement Agent Counsel, is material or omits to state any fact which, in the opinion of such counsel, is material
and is required to be stated therein or is necessary to make the statements therein not misleading, or that the General Disclosure
Package, any Issuer Free Writing Prospectus or the Prospectus or any amendment or supplement thereto contains an untrue statement
of fact which, in the opinion of such counsel, is material or omits to state any fact which, in the opinion of such counsel, is
material and is necessary in order to make the statements, in the light of the circumstances in which they were made, not misleading.


 


(c)
No Material Adverse Change. Since the date of the latest audited financial statements included in the Registration Statement,
the General Disclosure Package and the Prospectus or incorporated or deemed to be incorporated by reference therein as of the
date hereof, (i) neither the Company nor any Subsidiary shall have sustained any loss or interference with its business from fire,
explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action,
order or decree, otherwise than as set forth in the Registration Statement, the General Disclosure Package and the Prospectus,
and (ii) there shall not have been any change in the capital stock or long-term debt of the Company or any Subsidiary, or any
change, or any development involving a prospective change, in or affecting the business, management, financial position, stockholders’
equity or results of operations of the Company, otherwise than as set forth in the Registration Statement, the General Disclosure
Package and the Prospectus, the effect of which, in any such case described in clause (i) or (ii) of this paragraph (c)
is, in the judgment of the Placement Agent, so material and adverse as to make it impracticable or inadvisable to proceed with
the sale or delivery of the Securities on the terms and in the manner contemplated in the General Disclosure Package.


 


(d)
Adverse Governmental Actions. No action shall have been taken and no law, statute, rule, regulation or order shall have
been enacted, adopted or issued by any governmental agency or body which would prevent the issuance or sale of the Securities
or materially and adversely affect or potentially materially and adversely affect the business or operations of the Company or
any subsidiary; and no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction
shall have been issued which would prevent the issuance or sale of the Securities or materially and adversely affect or potentially
materially and adversely affect the business or operations of the Company or any subsidiary.


 


(e)
Market Conditions. Subsequent to the execution and delivery of this Agreement there shall not have occurred any of the
following: (i) trading in securities generally on the New York Stock Exchange, the Exchange or the NASDAQ Stock Market or in the
over-the-counter market, or trading in any securities of the Company on any exchange or in the over-the-counter market shall have
been suspended or materially limited, or minimum or maximum prices or maximum range for prices shall have been established on
any such exchange or such market by the Commission, by such exchange or market or by any other regulatory body or governmental
authority having jurisdiction, (ii) a banking moratorium shall have been declared by Federal or state authorities or a material
disruption has occurred in commercial banking or securities settlement or clearance services in the United States, (iii) the United
States shall have become engaged in hostilities, or the subject of an act of terrorism, or there shall have been an outbreak of
or escalation in hostilities involving the United States, or there shall have been a declaration of a national emergency or war
by the United States or (iv) there shall have occurred such a material adverse change in general economic, political or financial
conditions (or the effect of international conditions on the financial markets in the United States shall be such) as to make
it, in the judgment of the Placement Agent, impracticable or inadvisable to proceed with the sale or delivery of the Securities
on the terms and in the manner contemplated in the Registration Statement, the General Disclosure Package and the Prospectus.


 




    	 	26	 



    	 



    

 


(f)
Certificate of Designation. The Certificate of Designation shall have been filed with the Secretary of State of the State
of Delaware and become effective and the Company shall have delivered evidence of such filing and effectiveness to the Placement
Agent in form and substance satisfactory to the Placement Agent.


 


(g)
Opinion of Counsel for Company. At the Closing Date, the Placement Agent shall have received the favorable opinion and
negative assurance statement, dated as of the Closing Date, of Lowenstein Sandler LLP, counsel for the Company, in form and substance
reasonably satisfactory to the Placement Agent and its counsel.


 


(h)
Opinion of IP Counsel. At the Closing Date, the Placement Agent shall have received the favorable opinion and negative
assurances statement, dated as of the Closing Date, of MH2 Technology Law Group, LLP, as intellectual property counsel to the
Company, in form and substance reasonably satisfactory to the Placement Agent and its counsel.


 


(i)
Reliance. In rendering such opinions, such counsel may rely: (i) as to matters involving the application of laws other
than the laws of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to
the extent specified in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to
the Placement Agent) of other counsel reasonably acceptable to the Placement Agent, familiar with the applicable laws; and (ii)
as to matters of fact, to the extent they deem proper, on certificates or other written statements of officers of the Company
and officers of departments of various jurisdictions having custody of documents respecting the corporate existence or good standing
of the Company, provided that copies of any such statements or certificates shall be delivered to Placement Agent Counsel if requested.


 


(j)
Officers’ Certificate. The Company shall have furnished to the Placement Agent a certificate, dated the Closing Date
of its Chief Executive Officer, its President and its Chief Financial Officer stating that (i) such officers have carefully examined
the Registration Statement, the General Disclosure Package, and the Prospectus and, in their opinion, the Registration Statement
and each amendment thereto, as of the Applicable Time and as of the Closing Date did not include any untrue statement of a material
fact and did not omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading,
and the General Disclosure Package, as of the Applicable Time and as of the Closing Date, the Prospectus and each amendment or
supplement thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue statement of a material
fact and did not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
in which they were made, not misleading, (ii) since the effective date of the Registration Statement, no event has occurred which
should have been set forth in a supplement or amendment to the Registration Statement, the General Disclosure Package or the Prospectus,
(iii) to the best of their knowledge after reasonable investigation, as of the Closing Date, the representations and warranties
of the Company in this Agreement are true and correct and the Company has complied with all agreements and satisfied all conditions
on its part to be performed or satisfied hereunder at or prior to the Closing Date, and (iv) there has not been, subsequent to
the date of the most recent audited financial statements included or incorporated or deemed to be incorporated by reference in
the General Disclosure Package, any material adverse change in the financial position or results of operations of the Company,
or any change or development that, singularly or in the aggregate, would involve a material adverse change or a prospective material
adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of
the Company, except as set forth in the Prospectus.


 




    	 	27	 



    	 



    

 


(k)
Accountant’s Comfort Letter. At the time of the execution of this Agreement, the Placement Agent shall have received
from EisnerAmper LLP a letter, dated such date, in form and substance satisfactory to the Placement Agent, containing statements
and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect
to the financial statements and certain financial information of the Company contained in the Registration Statement, the General
Disclosure Package and the Prospectus.


 


(l)
Bring-down Comfort Letter. At the Closing Date, the Placement Agent shall have received from EisnerAmper LLP a letter,
dated as of the Closing Date, to the effect that they reaffirm the statements made in the letter furnished pursuant to subsection
(k) of this Section 5, except that the specified date referred to shall be a date not more than three Business Days prior to the
Closing Date.


 


(m)
Secretary’s Certificate. At the Closing Date, the Placement Agent shall have received a certificate of the Company
signed by the Secretary of the Company, dated the Closing Date certifying: (i) that each of the Company’s charter, bylaws
and Certificate of Designation is true and complete, has not been modified and is in full force and effect; (ii) that the resolutions
of the Company’s Board of Directors relating to the Offering are in full force and effect and have not been modified; (iii)
as to the accuracy and completeness of all correspondence between the Company or its counsel and the Commission; and (iv) as to
the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such certificate.


 


(n)
FINRA Clearance. On or before the date of this Agreement, the Placement Agent shall have received clearance from FINRA
as to the amount of compensation allowable or payable to the Placement Agent as described in the Registration Statement.


 


(o)
Lock-up Agreements. At the date of this Agreement, the Placement Agent shall have the Lock-Up Agreements substantially
in the form of Exhibit B hereto signed by each of the Lock-Up Parties.


 


(p)
Placement Agent’s Warrant Agreement. On the Closing Date, the Company shall have delivered to the Placement Agent
executed copies of the Placement Agent’s Warrant Agreement.


 


(q)
Additional Documents. At the Closing Date, the Placement Agent and Placement Agent Counsel shall have been furnished with
such documents and opinions as they may reasonably require for the purpose of enabling them to pass upon the issuance and sale
of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties, or
the fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance
and sale of the Securities as herein contemplated shall be reasonably satisfactory in form and substance to the Placement Agent
and counsel for the Placement Agent.


 




    	 	28	 



    	 



    

 


(r)
Approval of Inclusion. At the Closing Date, the Conversion Shares, the Dividend Shares and the Warrant Shares shall have
been approved for inclusion on the Exchange.


 


SECTION
6. Indemnification.


 


(a)
Indemnification of Placement Agent.


 


	 	(i)	General.
    Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless the Placement Agent, its affiliates
    and each of its and their respective directors, officers, members, employees, representatives, partners, shareholders, affiliates,
    counsel, agents, selected dealers and each person, if any, who controls any such Placement Agent and such selected dealers
    within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act (collectively the “Placement Agent
    Indemnified Parties,” and each an “Placement Agent Indemnified Party”), against any
    and all loss, liability, claim, damage and expense whatsoever (including but not limited to any and all legal or other expenses
    reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim
    whatsoever, whether arising out of any action between any of the Placement Agent Indemnified Parties and the Company or between
    any of the Placement Agent Indemnified Parties and any third party, or otherwise) to which they or any of them may become
    subject under the 1933 Act, the 1934 Act or any other statute or at common law or otherwise or under the laws of foreign countries
    (a “Claim”), (i) arising out of or based upon any untrue statement or alleged untrue statement of
    a material fact contained in (A) the Registration Statement, the General Disclosure Package, any Preliminary Prospectus or
    the Prospectus (or in any amendment or supplement thereto or document incorporated or deemed to be incorporated by reference
    therein); (B) any materials or information provided to prospective purchasers by, or with the approval of, the Company in
    connection with the marketing of the Offering, including any “road show” or prospective purchaser presentations
    made to prospective purchasers by the Company (whether in person or electronically); or (C) any application or other document
    or written communication (in this Section 5, collectively called “application”) executed by the Company or based
    upon written information furnished by the Company in any jurisdiction in order to qualify the Securities under the securities
    laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or any other national securities
    exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make
    the statements therein, in the light of the circumstances under which they were made, not misleading, unless such statement
    or omission was made in reliance upon, and in conformity with, the Placement Agent’s Information or (ii) otherwise arising
    in connection with or allegedly in connection with the Offering.


 




    	 	29	 



    	 



    

 


	 	(ii)	Procedure.
    If any action is brought against a Placement Agent Indemnified Party in respect of which indemnity may be sought against the
    Company pursuant to Section 6(a)(i), such Placement Agent Indemnified Party shall promptly notify the Company in writing of
    the institution of such action and the Company shall assume the defense of such action, including the employment and fees
    of counsel (subject to the approval of such Placement Agent Indemnified Party) and payment of actual expenses if a Placement
    Agent Indemnified Party requests that the Company do so. Such Placement Agent Indemnified Party shall have the right to employ
    its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of the such Placement
    Agent Indemnified Party unless (i) the employment of such counsel at the expense of the Company shall have been authorized
    in writing by the Company in connection with the defense of such action, or (ii) the Company shall not have employed counsel
    to have charge of the defense of such action, or (iii) such indemnified party or parties shall have reasonably concluded that
    there may be defenses available to it or them which are different from or additional to those available to the Company (in
    which case the Company shall not have the right to direct the defense of such action on behalf of the indemnified party or
    parties), in any of which events the reasonable fees and expenses of not more than one additional firm of attorneys selected
    by the Placement Agent Indemnified Party (in addition to local counsel) shall be borne by the Company, and shall be advanced
    by the Company. The Company shall not be liable for any settlement of any action effected without its consent (which shall
    not be unreasonably withheld). In addition, the Company shall not, without the prior written consent of the Placement Agent
    (which shall not be unreasonably withheld), settle, compromise or consent to the entry of any judgment in or otherwise seek
    to terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification or contribution
    may be sought hereunder (whether or not such Placement Agent Indemnified Party is a party thereto) unless such settlement,
    compromise, consent or termination (i) includes an unconditional release of each Placement Agent Indemnified Party, acceptable
    to such Placement Agent Indemnified Party, from all liabilities, expenses and claims arising out of such action for which
    indemnification or contribution may be sought and (ii) does not include a statement as to or an admission of fault, culpability
    or a failure to act, by or on behalf of any Placement Agent Indemnified Party.


 


	 	(iii)	Indemnification
    of the Company. The Placement Agent agrees to indemnify and hold harmless the Company, its directors, its officers who
    signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the 1933 Act or
    Section 20 of the 1934 Act ((collectively the “Company Indemnified Parties,” and each a “Company
    Indemnified Party”) against any and all loss, liability, claim, damage and expense described in the foregoing
    indemnity from the Company to the Placement Agent, as incurred, but only with respect to untrue statements or omissions, or
    alleged untrue statements or omissions made in the Registration Statement, any Preliminary Prospectus, the General Disclosure
    Package or Prospectus or any amendment or supplement thereto or in any application, in reliance upon, and in strict conformity
    with, the Placement Agent’s Information. In case any action shall be brought against any Company Indemnified Party based
    on any Preliminary Prospectus, the Registration Statement, the General Disclosure Package or Prospectus or any amendment or
    supplement thereto or any application, and in respect of which indemnity may be sought against the Placement Agent, the Placement
    Agent shall have the rights and duties given to the Company, and the Company Indemnified Party shall have the rights and duties
    given to the Placement Agent by the provisions of Section 6(a)(ii). Each Company Indemnified Party shall promptly notify the
    Placement Agent of the commencement of any litigation or proceedings such Company Indemnified Party, in connection with the
    issuance and sale of the Securities or in connection with the Registration Statement, the General Disclosure Package, or the
    Prospectus.


 




    	 	30	 



    	 



    

 


SECTION
7. Contribution.


 


(a)
Contribution Rights. If the indemnification provided for in Section 6 shall for any reason be unavailable to or insufficient
to hold harmless an indemnified party under Section 6(a) or 6(b) in respect of any loss, claim, damage or liability, or any action
in respect thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute
to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect
thereof, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company, on the one hand,
and the Placement Agent, on the other, from the Offering of the Securities, or (ii) if the allocation provided by clause (i) above
is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to
in clause (i) above but also the relative fault of the Company, on the one hand, and the Placement Agent, on the other, with respect
to the statements or omissions that resulted in such loss, claim, damage or liability, or action in respect thereof, as well as
any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Placement Agent
on the other with respect to such Offering shall be deemed to be in the same proportion as the total net proceeds from the Offering
of the Securities purchased under this Agreement (before deducting expenses) received by the Company as set forth in the table
on the cover page of the Prospectus, on the one hand, and the total Placement Fee received by the Placement Agent in connection
with the Offering as set forth in the table on the cover page of the Prospectus on the other hand. The relative fault shall be
determined by reference to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to
state a material fact relates to information supplied by the Company or the Placement Agent, the intent of the parties and their
relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the
Placement Agent agree that it would not be just and equitable if contributions pursuant to this Section 7(a) were to be determined
by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred
to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action in
respect thereof, referred to above in this Section 7(a) shall be deemed to include, for purposes of this Section 7(a), any legal
or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action
or claim. Notwithstanding the provisions of this Section 7(a) in no event shall the Placement Agent be required to contribute
any amount in excess of the total Placement Fee received by the Placement Agent less the amount of any damages which the Placement
Agent has otherwise paid or become liable to pay by reason of any untrue or alleged untrue statement, omission or alleged omission,
act or alleged act or failure to act or alleged failure to act. No person guilty of fraudulent misrepresentation (within the meaning
of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.


 




    	 	31	 



    	 



    

 


(b)
Contribution Procedure. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of
notice of the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof
is to be made against another party (“contributing party”), notify the contributing party of the commencement
thereof, but the failure to so notify the contributing party will not relieve it from any liability which it may have to any other
party other than for contribution hereunder. In case any such action, suit or proceeding is brought against any party, and such
party notifies a contributing party or its representative of the commencement thereof within the aforesaid 15 days, the contributing
party will be entitled to participate therein with the notifying party and any other contributing party similarly notified. Any
such contributing party shall not be liable to any party seeking contribution on account of any settlement of any claim, action
or proceeding affected by such party seeking contribution on account of any settlement of any claim, action or proceeding affected
by such party seeking contribution without the written consent of such contributing party. The contribution provisions contained
in this Section 7 are intended to supersede, to the extent permitted by law, any right to contribution under the 1933 Act, the
1934 Act or otherwise available


 


SECTION
8. Representations, Warranties and Agreements to Survive. The indemnities, covenants, agreements, representations, warranties
and other statements of the Company, as set forth in this Agreement or made by the Company pursuant to this Agreement, shall remain
in full force and effect, regardless of any investigation made by or on behalf of the Placement Agent, the Purchasers or any person
controlling any of them and shall survive delivery of and payment for the Securities. Notwithstanding any termination of this
Agreement, the indemnity and contribution agreements contained in Sections 6 and 7 and the covenants, representations, warranties
set forth in this Agreement shall not terminate and shall remain in full force and effect at all times.


 


SECTION
9. Effective Date of Agreement and Termination Thereof.


 


(a)
Effective Date. This Agreement shall become effective when both the Company and the Placement Agent have executed the same
and delivered counterparts of such signatures to the other party.


 




    	 	32	 



    	 



    

 


(b)
Termination. The Placement Agent shall have the right to terminate this Agreement at any time prior to any Closing Date,
(i) if any domestic or international event or act or occurrence has materially disrupted, or in your opinion will in the immediate
future materially disrupt, general securities markets in the United States; or (ii) if trading on the New York Stock Exchange,
the Exchange or the Nasdaq Stock Market LLC shall have been suspended or materially limited, or minimum or maximum prices for
trading shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the
Commission or any other government authority having jurisdiction; or (iii) if the United States shall have become involved in
a new war or an increase in major hostilities; or (iv) if a banking moratorium has been declared by a New York State or federal
authority; or (v) if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United
States securities markets; or (vi) if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake,
theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in your opinion,
make it inadvisable to proceed with the delivery of the Shares; or (vii) if the Company is in material breach of any of its representations,
warranties or covenants hereunder; or (viii) if the Placement Agent shall have become aware after the date hereof of such a material
adverse change in the conditions or prospects of the Company, or such adverse material change in general market conditions as
in the Placement Agent’s judgment would make it impracticable to proceed with the offering, sale and/or delivery of the
Shares. If this Agreement is terminated pursuant to this Section, such termination shall be without liability of any party to
any other party except as provided in Section 8 above and Section 9(c) below.


 


(c)
Expenses. Notwithstanding anything to the contrary in this Agreement, in the event that this Agreement shall not be carried
out for any reason whatsoever, within the time specified herein or any extensions thereof pursuant to the terms herein, the Company
shall be obligated to pay to the Placement Agent actual and accountable out-of-pocket expenses related to the transactions contemplated
herein then due and payable (including the fees and disbursements of Placement Agent Counsel) up to $37,500, inclusive of the
$25,000 advance for non-accountable expenses previously paid by the Company to the Placement Agent (the “Advance”)
and upon demand the Company shall pay the full amount thereof to the Placement Agent; provided, however, that such expense cap
in no way limits or impairs the indemnification and contribution provisions of this Agreement. Notwithstanding the foregoing,
any advance received by the Placement Agent will be reimbursed to the Company to the extent not actually incurred in compliance
with FINRA Rule 5110(f)(2)(C).


 


SECTION
12. Miscellaneous.


 


(a)
Notices. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall
be mailed (registered or certified mail, return receipt requested), personally delivered, sent by facsimile transmission or e-mail
and confirmed and shall be deemed given when so delivered, faxed, or e-mailed and confirmed or if mailed, two (2) days after such
mailing.


 




    	 	33	 



    	 



    

 


If
to the Placement Agent:


 


ThinkEquity

A Division of Fordham Financial Management, Inc.


17
State Street, 22nd Floor


New
York, NY 10005


Attn:
Mr. Eric Lord, Head of Investment Banking


Fax
No.: 212-349-2550


Email
address: el@think-equity.com


 


with
a copy (which shall not constitute notice) to:


 


Meister
Seelig & Fein LLP


125
Park Avenue, 7th Floor


New
York, New York 10017


Attn:
Kenneth S. Goodwin, Esq.


Fax
No.: 646-539-3663


Email
address: ksg@msf-law.com


Louis
Lombardo, Esq.


Fax
No.: 646-930-4710


Email
Address: ll@msf-law.com


 


If
to the Company:


 


Matinas
BioPharma Holdings, Inc.


1545
Route 206 South, Suite 302


Bedminster,
NJ 07921


Attn:
Mr. Jerome Jabbour, Chief Executive Officer


Fax
No.:


Email
address: jjabbour@matinasbiopharma.com


 


with
a copy (which shall not constitute notice) to:


 


Lowenstein
Sandler LLP


1251
Avenue of the Americas


New
York, NY 10020


Attn:
Steven M. Skolnick, Esq.


Fax
No.: 973-597-2477


Email
address: sskolnick@lowenstein.com


 


(b)
Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any
way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.


 


(c)
Amendment. This Agreement may only be amended by a written instrument executed by each of the parties hereto.


 




    	 	34	 



    	 



    

 


(d)
Entire Agreement. This Agreement (together with the other agreements and documents being delivered pursuant to or in connection
with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof and thereof,
and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.
Notwithstanding anything to the contrary set forth herein, it is understood and agreed by the parties hereto that all other terms
and conditions of that certain engagement letter between the Company and ThinkEquity, a division of Fordham Financial Management,
Inc., dated May 15, 2018, as amended, shall remain in full force and effect.


 


(e)
Successors; Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon
the Placement Agent, the Company, and their respective successors and assigns. This Agreement shall also inure to the benefit
of the Purchasers, and each of their respective successors and assigns, which shall be third party beneficiaries hereof. Nothing
expressed or mentioned in this Agreement is intended or shall be construed to give any person, other than the persons mentioned
in the preceding sentences, any legal or equitable right, remedy or claim under or in respect of this Agreement, or any provisions
herein contained, this Agreement and all conditions and provisions hereof being intended to be and being for the sole and exclusive
benefit of such persons and for the benefit of no other person; except that the representations, warranties, covenants, agreements
and indemnities of the Company contained in this Agreement shall also be for the benefit of the Placement Agent Indemnified Parties
and the indemnities of the Placement Agent shall be for the benefit of the Company Indemnified Parties.


 


(f)
Governing Law; Consent to Jurisdiction; Trial by Jury. This Agreement shall be governed by and construed and enforced in
accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby
agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought
and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District
of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any
objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to
be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested,
postage prepaid, addressed to it at the address set forth in Section 12(a) hereof. Such mailing shall be deemed personal service
and shall be legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies)
in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses
relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf
and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and the Placement Agent hereby irrevocably
waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising
out of or relating to this Agreement or the transactions contemplated hereby.


 


(g)
Execution in Counterparts. This Agreement may be executed in one or more counterparts, and by the different parties hereto
in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one
and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto
and delivered to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf
transmission shall constitute valid and sufficient delivery thereof.


 




    	 	35	 



    	 



    

 


(h)
Waiver, etc. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement shall
not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement or any
provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No
waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set
forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and
no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent
breach, non-compliance or non-fulfillment.


 


[Remainder
of the page intentionally left blank; signature page follows]


 




    	 	36	 



    	 



    

 


If
the foregoing is in accordance with your understanding of our agreement, please sign and return to the Company a counterpart hereof,
whereupon this instrument, along with all counterparts, will become a binding agreement between the Placement Agent and the Company
in accordance with its terms.


 


	 	Very truly yours, 
	 	 	 
	 	MATINAS BIOPHARMA HOLDINGS, INC.
	 	 	 
	 	By:	/s/
    Jerome D. Jabbour
	 	Name:	Jerome
    D. Jabbour
	 	Title:	Chief
    Executive Officer


 


Confirmed
and Accepted:


 


THINKEQUITY


 


	A Division of Fordham Financial Management, Inc.	 
	 	 	 
	By:	/s/
    Eric Lord	 
	Name:	Eric
    Lord	 
	Title:	Head
    of Investment Banking	 


 




    	 	37	 



    	 



    

 


SCHEDULE
A


 


General
Use Free Writing Prospectuses


 


None


 




    	 	 	 



    	 



    

 


SCHEDULE
B


 


Issuer
Free Writing Prospectuses


 


None.


 




    	 	 	 



    	 



    

 


SCHEDULE
C


 


Lock-Up
Parties


 


	Herbert
    Conrad	 
	 	 
	Jerome
    D. Jabbour	 
	 	 
	Dominick
    M. DiPaolo	 
	 	 
	Raphael
    J. Mannino	 
	 	 
	Gary
    Gaglione	 
	 	 
	Eric
    Ende	 
	 	 
	James
    S. Scibetta	 
	 	 
	Adam
    K. Stern	 
	 	 
	Matthew
    Wikler	 
	 	 
	Roelof
    Rongen	 


 




    	 	 	 



    	 



    

 


SCHEDULE
D


 


Subsidiaries


 


	Name	 	State
    of Incorporation
	 	 	 
	Matinas
    BioPharma, Inc.	 	Delaware
	 	 	 
	Matinas
    BioPharma Nanotechnologies, Inc.	 	Delaware


 




    	 	 	 



    	 



    

 


EXHIBIT
A


 


Form
of Placement Agent’s Warrant Agreement


 


THE
REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE
WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN,
PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE YEAR FOLLOWING THE CLOSING DATE (DEFINED BELOW) TO ANYONE OTHER
THAN (I) THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH
THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., OR OF ANY
SUCH UNDERWRITER OR SELECTED DEALER.


 


THIS
PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO JUNE 21, 2019. VOID AFTER 5:00 P.M., EASTERN TIME, JUNE 21, 2023.


 


WARRANT
TO PURCHASE COMMON STOCK 


 





MATINAS BIOPHARMA HOLDINGS,
INC.


 


Warrant
Shares: _______


 


Initial
Exercise Date: June 21, 2019


 


THIS
WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, ThinkEquity, a Division
of Fordham Financial Management, Inc. or its assigns (the “Holder”) is entitled, upon the terms and subject
to the limitations on exercise and the conditions hereinafter set forth, at any time on or after June 21, 2019 (the “Initial
Exercise Date”) and, in accordance with FINRA Rule 5110(f)(2)(G)(i), prior to at 5:00 p.m. (New York time) on the date
that is five (5) years following the Closing Date (the “Termination Date”) but not thereafter, to subscribe
for and purchase from Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), up to ______
shares (the “Warrant Shares”) of common stock, par value $0.0001 per share, of the Company (the “Common
Stock”), as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall
be equal to the Exercise Price, as defined in Section 2(b).


 




    	 	1	 



    	 



    

 


This
Warrant is issued in connection with an offering (the “Offering”) of Series B Convertible Preferred Stock,
par value $0.0001 per share, of the Company.


 


Section
1. Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings
indicated in this Section 1:


 


“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.


 


“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.


 


“Closing
Date” means the initial closing date of the Offering.


 


“Commission”
means the United States Securities and Exchange Commission.


 


“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock


 


“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


 


“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.


 


“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.


 


“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 




    	 	2	 



    	 



    

 


“Trading
Day” means a day on which the NYSE American is open for trading.


 


“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE American Market, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select
Market, or the New York Stock Exchange (or any successors to any of the foregoing).


 


“Transfer
Agent” means V Stock Transfer, LLC, the current transfer agent of the Company, with a mailing address of 18 Lafayette
Place, Woodmere, New York 11598 and a facsimile number of (646) 536-3179, and any successor transfer agent of the Company.


 


“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX as
applicable, (c) if Common Stock is not then listed or quoted for trading on the OTCQB or OTCQX and if prices for Common Stock
are then reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d) in all other cases,
the fair market value of the Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.


 


Section
2. Exercise.


 


a)
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of
the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books
of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within
two (2) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice
of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within five
(5) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting
in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise Form within two (2) Business Days of receipt of such notice. The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.


 




    	 	3	 



    	 



    

 


b)
Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $0.75, subject to adjustment
hereunder (the “Exercise Price”).


 


c)
Cashless Exercise. If at any time on or after the Initial Exercise Date, there is no effective registration statement registering,
or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may
also be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the Holder shall be
entitled to receive the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:


 


	 	(A)
    = 	the
    VWAP on the Trading Day immediately preceding the date on which Holder elects to exercise this Warrant by means of a “cashless
    exercise,” as set forth in the applicable Notice of Exercise;
	 	 	 
	 	(B)
    = 	the
    Exercise Price of this Warrant, as adjusted hereunder; and
	 	 	 
	 	(C)
    = 	the
    number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant
    if such exercise were by means of a cash exercise rather than a cashless exercise.


 


If
Warrant Shares are issued in such a “cashless exercise,” the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised,
and the holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares. The Company
agrees not to take any position contrary to this Section 2(c).


 


Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise
pursuant to this Section 2(c).


 




    	 	4	 



    	 



    

 


d)
Mechanics of Exercise.


 


i.
Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by its Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company
is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without
volume or manner-of-sale limitations pursuant to Rule 144 and, in either case, the Warrant Shares have been sold by the Holder
prior to the Warrant Share Delivery Date (as defined below), and otherwise by physical delivery of a certificate, registered in
the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is two
(2) Trading Days after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery
Date”). If the Warrant Shares can be delivered via DWAC, the transfer agent shall have received from the Company, at
the expense of the Company, any legal opinions or other documentation required by it to deliver such Warrant Shares without legend
(subject to receipt by the Company of reasonable back up documentation from the Holder, including with respect to affiliate status)
and, if applicable and requested by the Company prior to the Warrant Share Delivery Date, the transfer agent shall have received
from the Holder a confirmation of sale of the Warrant Shares (provided the requirement of the Holder to provide a confirmation
as to the sale of Warrant Shares shall not be applicable to the issuance of unlegended Warrant Shares upon a cashless exercise
of this Warrant if the Warrant Shares are then eligible for resale pursuant to Rule 144(b)(1)). The Warrant Shares shall be deemed
to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder
of record of such shares for all purposes, as of the date the Warrant has been exercised, with payment to the Company of the Exercise
Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to Section 2(d)(vi)
prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver to the Holder the Warrant
Shares subject to a Notice of Exercise by the second Trading Day following the Warrant Share Delivery Date, the Company shall
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20
per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after the second
Trading Day following such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.


 


ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.


 


iii.
Rescission Rights. If the Company fails to cause its Transfer Agent to deliver to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise; provided,
however, that the Holder shall be required to return any Warrant Shares or Common Stock subject to any such rescinded exercise
notice concurrently with the return to Holder of the aggregate Exercise Price paid to the Company for such Warrant Shares and
the restoration of Holder’s right to acquire such Warrant Shares pursuant to this Warrant (including, issuance of a replacement
warrant certificate evidencing such restored right).


 




    	 	5	 



    	 



    

 


iv.
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available
to the Holder, if the Company fails to cause its Transfer Agent to transmit to the Holder the Warrant Shares pursuant to an exercise
on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue
times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would
have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.


 


v.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the
Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction
multiplied by the Exercise Price or round up to the next whole share.


 




    	 	6	 



    	 



    

 


vi.
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid
by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly
executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for
any transfer tax incidental thereto. The Company shall pay all transfer agent fees required for same-day processing of any Notice
of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
required for same-day electronic delivery of the Warrant Shares.


 


vii.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.


 


viii.
Signature. This Section 2 and the exercise form attached hereto set forth the totality of the procedures required of the
Holder in order to exercise this Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required,
nor shall any medallion guarantee (or other type of guarantee or notarization) of any exercise form be required in order to exercise
this Warrant. No additional legal opinion, other information or instructions shall be required of the Holder to exercise this
Warrant. The Company shall honor exercises of this Warrant and shall deliver Shares underlying this Purchase Warrant in accordance
with the terms, conditions and time periods set forth herein.


 




    	 	7	 



    	 



    

 


e)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect
to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock
issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any
other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on
conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation
to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall
be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and
of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic
or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Company’s Transfer Agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing
to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock
shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company,
may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership
Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e)
shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day
after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which
may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to
a successor holder of this Warrant.


 


Section
3. Certain Adjustments.


 


a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.
For the purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the Company or any
Subsidiary thereof, as applicable, sells or grants any option to purchase, or sells or grants any right to reprice, or otherwise
disposes of or issues (or announces any offer, sale, grant or any option to purchase or other disposition) any Common Stock or
Common Stock Equivalents, at an effective price per share less than the Exercise Price then in effect.


 




    	 	8	 



    	 



    

 


b)
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could
have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result
in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).


 


c)
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than cash dividends)
or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of
capital or otherwise (including, without limitation, any distribution of shares or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (provided, however, to the extent that the Holder’s right to participate in any such
Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to
participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such
Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). To the
extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the
Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.


 




    	 	9	 



    	 



    

 


d)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making
or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would
have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the
Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable by holders of Common Stock as a result of such Fundamental Transaction
for each share of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without
regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the
obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is
exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder
to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being
for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant referring to the “Company” shall refer instead to the Successor Entity), and may exercise
every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect
as if such Successor Entity had been named as the Company herein.


 


e)
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.


 




    	 	10	 



    	 



    

 


f)
Notice to Holder.


 


i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the
Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.


 


ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed
a notice to the Holder at its last address as it shall appear upon the Warrant Register (as defined below) of the Company, at
least 20 calendar days prior to the applicable record or effective date hereinafter specified, stating (x) the date on which a
record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to
be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption,
rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common
Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to provide such
notice or any defect therein shall not affect the validity of the corporate action required to be specified in such notice. To
the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company
or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report
on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice
to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.


 


Section
4. Transfer of Warrant.


 


a)
Transferability. Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon exercise of
this Warrant shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative,
put, or call transaction that would result in the effective economic disposition of the securities by any person for a period
of 180 days immediately following the date of effectiveness or commencement of sales of the offering pursuant to which this Warrant
is being issued, except the transfer of any security:


 


i.
by operation of law or by reason of reorganization of the Company;


 


ii.
to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred
remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period;


 


iii.
if the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being
offered;


 


iv.
that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member
manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the
equity in the fund; or


 


v.
the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section
4(a) for the remainder of the time period.


 




    	 	11	 



    	 



    

 


Subject
to the foregoing restriction, any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all
rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender
of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant
substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination
or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion
of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant
in full, in which case, the Holder shall surrender this Warrant to the Company within three Trading Days of the date the Holder
delivers an assignment form to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith,
may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.


 


b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.


 


c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.


 


d)
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a
view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable
state securities law, except pursuant to sales registered or exempted under the Securities Act.


 


Section
5. Miscellaneous.


 


a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).


 




    	 	12	 



    	 



    

 


b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu
of such Warrant or stock certificate.


 


c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next
succeeding Trading Day.


 


d)
Authorized Shares.


 


The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market
upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise
of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and
payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).


 


Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant, and (iii) shall, so long as any of the Warrants are outstanding, take all action necessary
to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the
exercise of the Warrants, the number of shares of Common Stock as shall from time to time be necessary to effect the exercise
of the Warrants then outstanding (without regard to any limitations on exercise).


 




    	 	13	 



    	 



    

 


e)
Governing Law. This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning
the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State
of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York
or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.


 


f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.


 


g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting
any other provision of this Warrant or the Placement Agency Agreement, if the Company willfully and knowingly fails to comply
with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such
amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise
enforcing any of its rights, powers or remedies hereunder.


 


h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered in accordance with the notice provisions of the Placement Agency Agreement.


 


i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.


 


j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. Notwithstanding
the foregoing or anything else herein to the contrary, if the Company is for any reason unable to issue and deliver Warrant Shares
upon exercise of this Warrant as required pursuant to the terms hereof, the Company shall have no obligation to “net cash
settle” this Warrant.


 


k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.


 




    	 	14	 



    	 



    

 


l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.


 


m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.


 


n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.


 


(Signature
Page Follows)


 




    	 	15	 



    	 



    

 


IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first
above indicated.


 


	 	MATINAS BIOPHARMA HOLDINGS, INC.
	 	 	 
	 	By:	 
	 	Name:	Jerome
    D. Jabbour
	 	Title:	Chief
    Executive Officer


 




    	 	16	 



    	 



    

 


NOTICE
OF EXERCISE


 


TO:
MATINAS BIOPHARMA HOLDINGS, INC.


 


(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.


 


	 	(2)	Payment
    shall take the form of (check applicable box):



 


	 	-	in
    lawful money of the United States; or
	 	 	 
	 	-	if
    permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
    2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
    procedure set forth in subsection 2(c).


 


(3)
Please register and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:


 


______________________________


 


The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:


 


______________________________


 


______________________________


 


______________________________


 


[SIGNATURE
OF HOLDER]


 


Name
of Investing Entity: _______________________________________________________


 


Signature
of Authorized Signatory of Investing Entity: _________________________________


 


Name
of Authorized Signatory: ___________________________________________________


 


Title
of Authorized Signatory: ____________________________________________________


 


Date:
________________________________________________________________________


 




    	 	17	 



    	 



    

 


ASSIGNMENT
FORM


 


(To
assign the foregoing warrant, execute this form and supply required information. Do not use this form to exercise the warrant.)


 


FOR
VALUE RECEIVED, [____] all of or [_______] Warrant Shares of the foregoing Warrant and all rights evidenced thereby are hereby
assigned to


 


_______________________________________________
whose address is


 


_______________________________________________________________.


 


_______________________________________________________________


 


Dated:
___________________, _______


 


Holder’s
Signature: _____________________________


 


Holder’s
Address: ______________________________


 


NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatsoever. Officers of corporations and those acting in a fiduciary or other representative capacity
should file proper evidence of authority to assign the foregoing Warrant.


 




    	 	18	 



    	 



    

 


EXHIBIT
B


 


Form
of Lock-Up Agreement


 


LOCK-UP
LETTER AGREEMENT


 


ThinkEquity


A
Division of Fordham Financial Management, Inc.


17
State St., 22nd Fl


New
York, NY 10004


 


As
Placement Agent


 


Ladies
and Gentlemen:


 


The
undersigned understands that you (the “Placement Agent”) propose to enter into a Placement Agency Agreement
(the “Agreement”) pursuant to which the Placement Agent will offer, as agent, the shares (the “Stock”)
of Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”),
of Matinas BioPharma Holdings, Inc., a Delaware corporation (the “Company”), to the public (the “Offering”).


 


In
consideration of the execution of the Agreement by the Placement Agent, and for other good and valuable consideration, the undersigned
hereby irrevocably agrees that, without the prior written consent of the Placement Agent, the undersigned will not, directly or
indirectly, (1) offer for sale, sell, pledge, or otherwise transfer or dispose of (or enter into any transaction or device that
is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) any
shares of capital stock of the Company (including, without limitation, shares of common stock, par value $0.0001 per share, of
the Company (“Common Stock”) that may be deemed to be beneficially owned by the undersigned in accordance
with the rules and regulations of the Securities and Exchange Commission and shares of Common Stock that may be issued upon exercise
of any options or warrants) or securities convertible into or exercisable or exchangeable for Common Stock, (2) enter into any
swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of
ownership of shares of capital stock of the Company, whether any such transaction described in clause (1) or (2) above is to be
settled by delivery of capital stock of the Company or other securities, in cash or otherwise, (3) except as provided for below,
make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with
respect to the registration of any shares of Common Stock or securities convertible into or exercisable or exchangeable for Common
Stock or any other securities of the Company, or (4) publicly disclose the intention to do any of the foregoing for a period commencing
on the date hereof and ending on the 90th day after the date of the Prospectus relating to the Offering (such 90-day period, the
“Lock-Up Period”).


 




    	 	1	 



    	 



    

 


The
foregoing paragraph shall not apply to (a) transactions relating to shares of Common Stock or other securities acquired in the
open market after the completion of the Offering, provided that no filing under Section 16(a) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), shall be required or shall be voluntarily made in connection
with such transfers; (b) bona fide gifts of shares of any class of the Company’s capital stock or any security convertible
into Common Stock, in each case that are made exclusively between and among the undersigned or members of the undersigned’s
family, or affiliates of the undersigned, including its partners (if a partnership) or members (if a limited liability company);
(c) any transfer of shares of Common Stock or any security convertible into Common Stock by will or intestate succession upon
the death of the undersigned; (d) transfer of shares of Common Stock or any security convertible into Common Stock to an immediate
family member (for purposes of this Lock-Up Letter Agreement, “immediate family” shall mean any relationship by blood,
marriage or adoption, not more remote than first cousin) or any trust, limited partnership, limited liability company or other
entity for the direct or indirect benefit of the undersigned or any immediate family member of the undersigned; provided that,
in the case of clauses (b)- (d) above, it shall be a condition to any such transfer that (i) the transferee/donee agrees to be
bound by the terms of this Lock-Up Letter Agreement (including, without limitation, the restrictions set forth in the preceding
sentence) to the same extent as if the transferee/donee were a party hereto, (ii) each party (donor, donee, transferor or transferee)
shall not be required by law (including without limitation the disclosure requirements of the Securities Act of 1933, as amended,
(the “Securities Act”) and the Exchange Act) to make, and shall agree to not voluntarily make, any filing
or public announcement of the transfer or disposition prior to the expiration of the 90-day period referred to above, and (iii)
the undersigned notifies the Placement Agent at least two business days prior to the proposed transfer or disposition; (e) the
transfer of shares to the Company to satisfy withholding obligations for any equity award granted pursuant to the terms of the
Company’s stock option/incentive plans, such as upon exercise, vesting, lapse of substantial risk of forfeiture, or other
similar taxable event, in each case on a “cashless” or “net exercise” basis (which, for the avoidance
of doubt shall not include “cashless” exercise programs involving a broker or other third party), provided
that as a condition of any transfer pursuant to this clause (e), that if the undersigned is required to file a report under Section
16(a) of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock or any securities convertible
into or exercisable or exchangeable for Common Stock during the Lock-Up Period, the undersigned shall include a statement in such
report, and if applicable an appropriate disposition transaction code, to the effect that such transfer is being made as a share
delivery or forfeiture in connection with a net value exercise, or as a forfeiture or sale of shares solely to cover required
tax withholding, as the case may be; (f) transfers of shares of Common Stock or any security convertible into or exercisable or
exchangeable for Common Stock pursuant to a bona fide third party tender offer made to all holders of the Common Stock, merger,
consolidation or other similar transaction involving a change of control (as defined below) of the Company, including voting in
favor of any such transaction or taking any other action in connection with such transaction, provided that in the event
that such merger, tender offer or other transaction is not completed, the Common Stock and any security convertible into or exercisable
or exchangeable for Common Stock shall remain subject to the restrictions set forth herein; (g) the exercise of warrants or the
exercise of stock options granted pursuant to the Company’s stock option/incentive plans or otherwise outstanding on the
date hereof; provided, that the restrictions shall apply to shares of Common Stock issued upon such exercise or conversion;
(h) the establishment of any contract, instruction or plan that satisfies all of the requirements of Rule 10b5-1 (a “Rule
10b5-1 Plan”) under the Exchange Act; provided, however, that no sales of Common Stock or securities
convertible into, or exchangeable or exercisable for, Common Stock, shall be made pursuant to a Rule 10b5-1 Plan prior to the
expiration of the Lock-Up Period; provided further, that the Company is not required to report the establishment of such
Rule 10b5-1 Plan in any public report or filing with the Commission under the Exchange Act during the lock-up period and does
not otherwise voluntarily effect any such public filing or report regarding such Rule 10b5-1 Plan; and (i) any demands or requests
for, exercise any right with respect to, or take any action in preparation of, the registration by the Company under the Act of
the undersigned’s shares of Common Stock, provided that no transfer of the undersigned’s shares of Common Stock
registered pursuant to the exercise of any such right and no registration statement shall be filed under the Act with respect
to any of the undersigned’s shares of Common Stock during the Lock-Up Period. For purposes of clause (f) above, “change
of control” shall mean the consummation of any bona fide third party tender offer, merger, purchase, consolidation or other
similar transaction the result of which is that any “person” (as defined in Section 13(d)(3) of the Exchange Act),
or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of a majority of total
voting power of the voting stock of the Company.


 




    	 	2	 



    	 



    

 


The
undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar
against the transfer of the undersigned’s securities subject to this Lock-Up Letter Agreement except in compliance with
this Lock-Up Letter Agreement.


 


It
is understood that, if the Company notifies the Placement Agent that it does not intend to proceed with the Offering, if the Agreement
does not become effective, or if the Agreement (other than the provisions thereof which survive termination) shall terminate or
be terminated prior to the Offering, the undersigned will be released from its obligations under this Lock-Up Letter Agreement.


 


The
undersigned understands that the Company and the Placement Agent will proceed with the Offering in reliance on this Lock-Up Letter
Agreement.


 


Whether
or not the Offering actually occurs depends on a number of factors, including market conditions. Any Offering will only be made
pursuant to a Placement Agency Agreement, the terms of which are subject to negotiation between the Company and the Placement
Agent.


 


This
Lock-Up Letter Agreement shall automatically terminate upon the earliest to occur, if any, of (1) the termination of the Agreement
before the Offering or (2) [DATE], in the event that the Agreement has not been executed by that date.


 


[Signature
page follows]


 




    	 	3	 



    	 



    

 


The
undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Letter
Agreement and that, upon request, the undersigned will execute any additional documents necessary in connection with the enforcement
hereof. Any obligations of the undersigned shall be binding upon the heirs, personal representative, successors and assigns of
the undersigned.


 


	 	Very truly yours,
	 	 	 
	 	By:	 
	 	Name:
    	 
	 	Title:	 


 


Dated:
_______________